Rare Cancer News & Clinical Trials » Endocrine/Neuroendocrine

Endocrine/Neuroendocrine (235 unread)

Primary merkel cell carcinoma clinically presenting as deep oedematous mass of the groin.

Fetched: September 1st, 2010, 9:31am CDT

Primary merkel cell carcinoma clinically presenting as deep oedematous mass of the groin.

Eur J Med Res. 2010 Jun 28;15(6):274-6

Authors: Gambichler T, Kobus S, Kreuter A, Wieland U, StÃ¼cker M

Merkel cell carcinoma (MCC) is a relatively rare, polyomavirus associated, primary neuroendocrine carcinoma of the skin which is usually arising from dermal skin layers. However, the origin of MCC in the subcutaneous tissue is debatable. We report a 58-year-old female patient with an oedematous mass on her left groin that was firm in consistency and had no discoloration or other visible abnormality of the overlying skin. On histology and immunohistology the tumour was consistent with the diagnosis of MCC showing a predominant subcutanous growth pattern. Pelvic magnetic resonance tomography revealed a tumour conglomerate reaching from the subcutis of the left groin to the left paraaortal and parailiacal region indicating widespread lymphogenic metastisation. Despite complete medical work-up no other MCC primary could be detected. In conclusion, predominant subcutaneous growth pattern as well as tumour localization in the groin are uncommon features of MCC. MCC showing the aforementioned features may be associated with significant delay of diagnosis and therefore represents an unfavourable prognostic factor.

PMID: 20696637 [PubMed - indexed for MEDLINE]

Merkel cell carcinoma: clinical characteristics, markers, staging and treatment.

Fetched: September 1st, 2010, 9:31am CDT

Merkel cell carcinoma: clinical characteristics, markers, staging and treatment.

J Drugs Dermatol. 2010 Jul;9(7):779-84

Authors: Lien MH, Baldwin BT, Thareja SK, Fenske NA

Merkel cell carcinoma (MCC) is a highly aggressive neoplasm affecting primarily the elderly Caucasian population. Earlier detection of this neoplasm may achieve a better prognosis and an improved outcome. Here, the authors review the typical clinical features of MCC to serve as a reference tool for clinicians in determining when a biopsy may be warranted. An array of immunohistochemical markers may be utilized to differentiate MCC from other neuroendocrine tumors. The staging and concomitant treatment options of MCC are discussed. In addition, the authors review therapeutic advances for treatment of MCC utilizing an array of target proteins.

PMID: 20677532 [PubMed - indexed for MEDLINE]

Dermatoscopic features of cutaneous atypical fibroxanthoma: three cases.

Fetched: September 1st, 2010, 9:31am CDT

Dermatoscopic features of cutaneous atypical fibroxanthoma: three cases.

Clin Exp Dermatol. 2009 Dec;34(8):e898-900

Authors: Bugatti L, Filosa G

Atypical fibroxanthoma (AFX) is an uncommon, low-grade, malignant, spindle-cell tumour of fibrohistiocytic histogenesis, which can mimic other malignant skin tumours, such as basal and squamous cell carcinoma (CC), melanoma, and Merkel cell carcinoma (MCC). Three cases of AFX were examined by dermatoscopy, which revealed white areas and an atypical polymorphous vascular pattern characterized by the concurrence of different structures: linear, dotted, hairpin, arborescent and highly tortuous vessels, irregularly distributed over the surface. Seborrhoeic elements and photoageing may be accompanying features depending on the anatomical location of the AFX. AFX may be added to the list of slightly pigmented, reddish, malignant cutaneous tumours, such as SCC, MCC, amelanotic/hypomelanotic melanoma and eccrine porocarcinoma, which display prominent and chaotic dermatoscopic neoangiogenetic features in more advanced stages of proliferation.

PMID: 20055861 [PubMed - indexed for MEDLINE]

Permalink for 'Immunological detection of viral large T antigen identifies a subset of Merkel cell carcinoma tumors with higher viral abundance and better clinical outcome.'

Immunological detection of viral large T antigen identifies a subset of Merkel cell carcinoma tumors with higher viral abundance and better clinical outcome.

Fetched: September 1st, 2010, 9:31am CDT

Immunological detection of viral large T antigen identifies a subset of Merkel cell carcinoma tumors with higher viral abundance and better clinical outcome.

Int J Cancer. 2010 Sep 1;127(6):1493-6

Authors: Bhatia K, Goedert JJ, Modali R, Preiss L, Ayers LW

PMID: 20041469 [PubMed - indexed for MEDLINE]

Spontaneous regression of advanced merkel-cell-like small cell carcinoma of the parotid gland.

Fetched: September 1st, 2010, 9:31am CDT

Spontaneous regression of advanced merkel-cell-like small cell carcinoma of the parotid gland.

Br J Oral Maxillofac Surg. 2010 Apr;48(3):199-200

Authors: Mulder DC, Rosenberg AJ, Storm-Bogaard PW, Koole R

Small cell carcinomas of the salivary gland are rare. We present a case of spontaneous regression of an advanced merkel-cell-like small cell carcinoma of the parotid gland.

PMID: 19619917 [PubMed - indexed for MEDLINE]

[Sentinel lymph node biopsy for lymphophilic conjunctival and eyelid tumors: report of 8 cases]

Fetched: September 1st, 2010, 9:31am CDT

[Sentinel lymph node biopsy for lymphophilic conjunctival and eyelid tumors: report of 8 cases]

Rev Laryngol Otol Rhinol (Bord). 2009;130(4-5):231-4

Authors: Maalouf T, George JL, Geoffrois L, Olivier P, Dolivet G

OBJECTIVE: To report our experience in sentinel lymph node biopsy for lymphophilic conjunctival and eyelid tumours. METHODS AND RESULTS: Preliminary study (2005-2007) on 8 patients with conjunctival and or eyelid tumours (melanomas, epidermoid carcinoma, Merkel cell carcinoma). All patients underwent preoperative lymphoscintigraphy 18 FdG pet CT Surgery was performed with complete neck dissection. Sentinel nodes and other nodes harvested were processed separately for histopathologic study; the sentinel were confirmed as histologicaly positive for five patients. Additional positive nodes were found in two out of those five patients. No positive lymph node was found in patients with negative lymphoscintigraphy. After a follow up ranging from 12 to 43 months: two patients died, and 6 are free of disease. CONCLUSIONS: These results demonstrate a very hight level of invaded NO lymph node and confirm the interest of sentinel node technique for optimisation of the therapeutic strategy in lymphophilic conjunctival and eyelid tumours.

PMID: 20597403 [PubMed - indexed for MEDLINE]

Dermatopathology of skin cancer in solid organ transplant recipients.

Fetched: August 17th, 2010, 9:13am CDT

Dermatopathology of skin cancer in solid organ transplant recipients.

Transplant Rev (Orlando). 2010 Aug 13;

Authors: Stoff B, Salisbury C, Parker D, O'Reilly Zwald F

Skin cancers occur more frequently in solid organ transplant recipients relative to the general population. Transplant recipients are at particularly high risk of squamous cell carcinoma, with up to a 100-fold increase in the relative risk when compared to the nontransplanted population. This compares with a 10- to 16-fold increase in basal cell carcinoma for renal transplant recipients. An increased incidence of melanoma in transplant patients has also been reported. Other types of skin cancer associated with immunosuppression in transplant patients include Kaposi sarcoma, Merkel cell carcinoma, and posttransplant lymphoproliferative disorder. This review discusses the epidemiology and pertinent pathologic features of each of these tumors. A brief clinical management strategy is outlined. In addition, the contribution of viral induced carcinogenesis with respect to Kaposi sarcoma, Merkel cell carcinoma, and posttransplant lymphoproliferative disorder is discussed.

PMID: 20709518 [PubMed - as supplied by publisher]

Merkel Cell Carcinoma: 27-Year Experience at the Peter MacCallum Cancer Centre.

Fetched: August 17th, 2010, 9:13am CDT

Merkel Cell Carcinoma: 27-Year Experience at the Peter MacCallum Cancer Centre.

Int J Radiat Oncol Biol Phys. 2010 Aug 12;

Authors: Hui AC, Stillie AL, Seel M, Ainslie J

PURPOSE: To retrospectively evaluate the treatment outcome of patients with Merkel cell carcinoma after local and/or regional treatment. METHODS AND MATERIALS: Patients presenting to our center between January 1980 and July 2006 with Merkel cell carcinoma and without distant metastases were reviewed. The primary endpoint was locoregional control. Secondary endpoints were distant recurrence, survival and treatment toxicity. RESULTS: A total of 176 patients were identified. The median age was 79 years. The median follow-up was 2.2 years for all patients and 3.9 years for those alive at the last follow-up visit. The most common primary site was the head and neck (56%), and 62 patients(35%) had regional disease at presentation. The initial surgery to the primary tumor involved (wide) local excision in 140 patients and biopsy only in 28 patients (8 patients had no identifiable primary tumor); 33 patients underwent nodal surgery. Of the 176 patients, 165 (94%) underwent radiotherapy (RT) and 29 of them also underwent concurrent chemotherapy. The median radiation dose was 50 Gy (range, 18-60). Locoregional recurrence developed in 33 patients(19%), with a median interval to recurrence of 8 months. Distant metastases developed in 43 patients(24%). Age, primary tumor size, and RT (no RT vs. <45 Gy vs. >/=45 Gy) were predictive of locoregional control on univariate analysis. However, only RT remained significant on multivariate analysis. The estimated 5-year actuarial rate for locoregional control, progression-free survival, and overall survival was 76%, 60%, and 45%, respectively. CONCLUSION: The locoregional control rate for Merkel cell carcinoma in our study was comparable to those from other series using combined modality treatment with RT an integral part of treatment.

PMID: 20708847 [PubMed - as supplied by publisher]

Neuroendocrine tumors and their association with rare tumors: observation of 4 cases.

Fetched: August 17th, 2010, 9:13am CDT

Neuroendocrine tumors and their association with rare tumors: observation of 4 cases.

Eur Rev Med Pharmacol Sci. 2010 Jul;14(7):577-88

Authors: Cirillo F

PURPOSE: Neuroendocrine tumors are rare neoplasms, with an incidence of about 1/100,000/year. The association between digestive neuroendocrine tumors and epithelial tumors is known, accounting for about 10% of cases, whilst in a very small number of other cases an association with other low incidence tumors has been observed. METHODS: During the past 19 years the Rare Hormonal Tumors Group of the Istituti Ospitalieri in Cremona, Italy has observed 300 patients affected by neuroendocrine tumors. We report here on four cases in which there was an unusual association with other rare neoplasms. RESULTS: Overall, four of the 300 observed cases (1.3%) showed an unusual association with rare nonepithelial neoplasms: (1) gastric carcinoid and glioblastoma multiforme; (2) Merkel cell tumor and squamous cell carcinoma of the skin; (3) medullary thyroid carcinoma, yolk sac tumor of the testis and gastrointestinal stromal tumor (GIST); (4) gastric carcinoid and gastrointestinal stromal tumor (GIST). DISCUSSION: There cases are of interest not only from an epidemiological point of view, but also offer insight into possible geno-phenotypical implications. The c-kit expression, typical of GISTs but observed also in other epithelial and neuroendocrine tumors, not only broadens the possibility to gain insight into the carcinogenesis of these neoplasms, but also opens the field to possible new therapeutic opportunities using multitargeted molecules. The contemporaneous presence of other lesions, such as the Merkel cell tumor and the squamous cell carcinoma of the skin can be interpreted as an answer by the cell to the same mutagenic stimulus. In other cases, where a possible link is not yet found which could explain the synchronism or metachronism of low incidence neoplasms, it remains possible that the associations are entirely coincidental. We await for new instruments which could help us demonstrate the possible relationships between low incidence neoplasms.

PMID: 20707247 [PubMed - in process]

Papillomavirus infection requires {gamma} secretase.

Fetched: August 17th, 2010, 9:13am CDT

Papillomavirus infection requires {gamma} secretase.

J Virol. 2010 Aug 11;

Authors: Karanam B, Peng S, Li T, Buck C, Day PM, Roden RB

The mechanism by which papillomaviruses breach cellular membranes to deliver their genomic cargo to the nucleus is poorly understood. Here we show that infection by a broad range of papillomavirus types requires the intra-membrane protease gamma-secretase. The gamma-secretase inhibitor (S,S)-2-[2-(3,5-Difluorophenyl)-acetylamino]-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-propionamide (compound XXI) inhibits infection in vitro by all types of papillomavirus pseudovirions tested with IC50 of 130-1000pM, regardless of reporter construct, and without impacting cellular viability. Conversely, XXI does not inhibit in vitro infection by adenovirus or pseudovirions derived from the polyomaviruses BK or Merkel Cell polyomavirus. Vaginal application of XXI prevents infection of the mouse genital tract by HPV16 pseudovirions. Nicastrin and presenilin-1 are essential components of the gamma-secretase complex, and mouse embryo fibroblasts deficient in any one of these components were not infected by HPV16, whereas wild type and beta-secretase (BACE1)-deficient cells were susceptible. Neither the uptake of HPV16 into Lamp-1+ perinuclear vesicles, nor the disassembly of capsid to reveal both internal L1 and L2 epitopes and BrdU-labeled encapsidated DNA are dependent upon gamma-secretase activity. However, blockade of gamma-secretase activity by XXI prevents the BrdU-labeled DNA encapsidated by HPV16 from reaching the ND10 subnuclear domains. Since prior studies indicate that L2 is critical for endosomal escape and targeting of the viral DNA to ND10 and that gamma-secretase is located in endosomal membranes, our findings suggest that either L2 or an intracellular receptor are cleaved by gamma-secretase as papillomavirus escapes the endosome.

PMID: 20702627 [PubMed - as supplied by publisher]

Human Papillomavirus (HPV) and Merkel Cell Polyomavirus (MCPyV) in non small cell lung cancer.

Fetched: August 17th, 2010, 9:13am CDT

Human Papillomavirus (HPV) and Merkel Cell Polyomavirus (MCPyV) in non small cell lung cancer.

Exp Mol Pathol. 2010 Aug 7;

Authors: Joh J, Jenson AB, Moore GD, Rezazedeh A, Slone SP, Ghim SJ, Kloecker GH

Certain types of human papillomavirus (HPV) induce cancers, especially cervical cancers in women. A meta-analysis of the literature suggests that HPV is also associated with 20%-25% of non small cell lung carcinoma (NSCLC). Merkel cell Polyomavirus (MCPyV) causes most Merkel cell carcinomas in immunocompromised hosts, and is associated with some squamous carcinomas of skin in immunocompetent individuals. Since both oncogenic viruses appear to involve the tonsils and, therefore, have clear access to the lungs, we examined that the possible association of HPV and MCPyV infections with lung cancers, especially, NSCLC. DNAs were extracted from 51 frozen tissues from 30 lung cancer patients, and examined for the presence of HPV and MCPyV by PCR and DNA sequencing analysis. Clinical data was correlated with the viral status. HPVs were only detected in 5 adenocarcinomas (16.7% of all lung cancers examined). Three were positive for HPV-16, 1 for HPV-11 and 1 had an unknown HPV type DNA. None was identified in benign tissue. MCPyV DNA was detected in 5 NSCLCs (16.7%). Three of the 5 were identified in squamous carcinomas, 1 in adenocarcinoma, and 1 in an unspecified NSCLC. Two additional samples were positive for MCPyV DNA within benign adjacent lung tissue only. In one adenocarcinoma, HPV-11 was identified in an adenocarcinoma, and MCPyV DNA was detected in the adjacent "benign" tissue. HPV and MCPyV were directly associated with 33.3% of NSCLC. Further studies are necessary to determine if polyomavirus and papillomavirus are necessary risk factors for some cases of NSCLC.

PMID: 20699096 [PubMed - as supplied by publisher]

Characterization of a New Monoclonal Antibody Against PAX5/BASP in 1525 Paraffin-embedded Human and Animal Tissue Samples.

Fetched: August 17th, 2010, 9:13am CDT

Characterization of a New Monoclonal Antibody Against PAX5/BASP in 1525 Paraffin-embedded Human and Animal Tissue Samples.

Appl Immunohistochem Mol Morphol. 2010 Aug 6;

Authors: Agostinelli C, Sabattini E, GjÃ¸rret JO, Righi S, Rossi M, Mancini M, Piccaluga PP, Bacci F, Marafioti T, Bettini G, Falini B, Pileri SA

INTRODUCTION: We describe the newly generated DAK-PAX5 monoclonal antibody raised against a fixation-resistant epitope of the human PAX5/BSAP molecule. MATERIALS AND METHODS: Following Western-blot, absorption, and chess-board titration tests, and optimization of antigen-retrieval and detection methods, DAK-Pax5 was used in parallel with a reference antibody (clone 24) on tissue micro-arrays (TMAs) constructed from normal human and animal tissues and from hematologic and nonhematologic human malignancies. Such TMAs were also tested with an anti-PAX2 antibody. RESULTS: DAK-Pax5 reacted with normal human and animal B-cells and with 460/473 B-cell non-Hodgkin lymphomas (B-NHLs). All plasmacytomas/plasmablastic tumors (n=13) and T/NK-cell neoplasms (n=264) turned out consistently negative as did acute myelogenous leukaemias (n=19) except 2 carrying t(8;21). Positivity was found in 6/6 and 155/169 lymphocyte predominant and classical HLs, respectively, although the staining intensity varied through cases. Among 521 nonhematologic malignancies, DAK-Pax5 reacted with 22/399 carcinomas (4/11 neuroendocrine, 2/4 Merkel-cell, 4/21 prostatic, 1/11 urothelial, 1/26 renal, 2/12 cervical squamous-cell, 3/13 ovarian, and 5/75 colonic). When compared with clone 24, DAK-Pax5 produced a stronger positivity in most if not all B-NHLs and HLs. No cross-reactivity with the anti-PAX2 antibody was recorded. DISCUSSION: DAK-Pax5 represents a new reliable tool for diagnostics and research.

PMID: 20697266 [PubMed - as supplied by publisher]

Prevalence of Merkel Cell Polyomavirus among Swiss Merkel Cell Carcinoma Patients.

Fetched: August 8th, 2010, 7:33pm CDT

Prevalence of Merkel Cell Polyomavirus among Swiss Merkel Cell Carcinoma Patients.

Dermatology. 2010 Jul 30;

Authors: Mangana J, Dziunycz P, Kerl K, Dummer R, Cozzio A

Background: Merkel cell carcinoma (MCC) is a malignant neuroendocrine neoplasm which shares structural and immunohistochemical features with neuroectodermally derived cells. One hypothesis claims that it arises from Merkel cells, highly innervated neuroendocrine cells involved in mechanoreception in the skin. The incidence rate of this cancer increases with age and sun exposure as well as after immunosuppression. Recently, the clonal integration of a newly identified polyomavirus called Merkel cell polyomavirus (MCPyV) was reported in up to 80% of MCC tissue. Here we report the incidence rate of MCPyV in MCC patients in Switzerland. Methods: We performed polymerase chain reaction in a collection of 32 samples obtained from pathology institutes around Switzerland. We used three different published primer sets. As control groups we used 7 squamous cell carcinoma samples and 11 normal skin samples. Conclusions: We detected viral DNA in 20 out of 30 cases of MCC and in 0 out of 19 control samples. The presence of viral DNA in 66.6% of our MCC tissue specimens confirms the high prevalence of MCPyV in MCC patients described in American, German, French and Hungarian patient collections.

PMID: 20689250 [PubMed - as supplied by publisher]

[Management for 145 cases of Merkel cell carcinoma.]

Fetched: August 8th, 2010, 7:33pm CDT

[Management for 145 cases of Merkel cell carcinoma.]

Bull Cancer. 2010 Aug 4;

Authors: Assouline A, Tai P, Levy A, Yu E, Dong Lian J, Joseph K, Miale T, Krzisch C

PurposeMerkel cell carcinoma (MCC)/primary cutaneous neuroendocrine carcinoma is a rare and aggressive malignant tumor. Optimal therapeutic strategy has not yet been established.Patients and methodsManagement of 145 patients from five centres was analysed. These data included ages, pathological stages, disease sites, histological and treatment details. Cause-specific (CSS) and overall survivals (OS) were analyzed by the Log-rank and Kaplan-Meier methods.ResultsMedian age was 78 years (47-95.2). We experienced 37 local, 37 regional and 15 distant relapses. In case of relapse, salvage therapy has been proposed whenever the general state of health condition of patient permitted it.ConclusionOur results for the treatment of relapse encourage multidisciplinary approach. Multicenter prospective trials are still needed to clarify and validate the optimal strategy.

PMID: 20682483 [PubMed - as supplied by publisher]

Pathology quiz case 2. Merkel cell carcinoma (MCC) of the left auricle.

Fetched: August 8th, 2010, 7:33pm CDT

Pathology quiz case 2. Merkel cell carcinoma (MCC) of the left auricle.

Arch Otolaryngol Head Neck Surg. 2010 Jul;136(7):745, 747-8

Authors: Sneshkoff NT, Freeman JH, Liming BJ

PMID: 20644078 [PubMed - indexed for MEDLINE]

A comparative study of Merkel cell, BK and JC polyomavirus infections in renal transplant recipients and healthy subjects.

Fetched: August 4th, 2010, 9:26am CDT

A comparative study of Merkel cell, BK and JC polyomavirus infections in renal transplant recipients and healthy subjects.

J Clin Virol. 2010 Jul 26;

Authors: Husseiny MI, Anastasi B, Singer J, Lacey SF

BACKGROUND: Merkel cell carcinoma (MCC) is a rare skin cancer associated with immunosuppression and the integration of Merkel cell polyomavirus (MCPyV) DNA into the tumor cell genome. Little is known about the natural history of MCPyV infection. OBJECTIVES: To investigate the presence of MCPyV, BK and JC polyomaviruses in serum and urine from immunosuppressed kidney transplant patients (KTx) and a control group of normal volunteers. STUDY DESIGN: Quantitative real-time PCR (q-PCR) was used to assess MCPyV, BKV and JCV viral load in urine and serum samples collected from normal donors (Group A), prospectively enrolled KTx patients (Group B) and from KTx with documented BK reactivation and/or nephropathy (Group C). RESULTS: Low levels of MCPyV viruria was seen in 15% of the subjects in Group A, 30% of Group B, and was not detected in Group C. No individuals in the study developed MCPyV viremia. BK viruria was seen in 5% of Group A, 30% of Group B, and 100% of Group C. Consistent with previous reports, the mean BKV urinary load was significantly higher in immunosuppressed patients compared to non-immunosuppressed controls and also higher in urine compared to serum samples. CONCLUSIONS: Like BKV and JCV, MCPyV is likely a common infection in adult humans. Low level shedding of MCPyV in urine was similar in immunosuppressed organ transplant recipients to non-immunosuppressed subjects. However, MCPyV was not detected and JCV was infrequent in samples from KTx patients with clinical BKV reactivation.

PMID: 20667770 [PubMed - as supplied by publisher]

Unsupervised skin lesions border detection via two-dimensional image analysis.

Fetched: August 4th, 2010, 9:26am CDT

Unsupervised skin lesions border detection via two-dimensional image analysis.

Comput Methods Programs Biomed. 2010 Jul 19;

Authors: Abbas Q, FondÃ³n I, Rashid M

The skin cancer was analyzed by dermoscopy helpful for dermatologists. The classification of melanoma and carcinoma such as basal cell, squamous cell, and merkel cell carcinomas tumors can be increased the sensitivity and specificity. The detection of an automated border is an important step for the correctness of subsequent phases in the computerized melanoma recognition systems. The artifacts such as, dermoscopy-gel, specular reflection and outline (skin lines, blood vessels, and hair or ruler markings) were also contained in the dermoscopic images. In this paper, we present an unsupervised approach for multiple lesion segmentation, modification of Region-based Active Contours (RACs) as well as artifact diminution steps. Iterative thresholding is applied to initialize level set automatically; the stability of curves is enforced by maximum smoothing constraints on Courant-Friedreichs-Lewy (CFL) function. The work has been tested on dermoscopic database of 320 images. The border detection error is quantified by five distinct statistical metrics and manually used to determine the borders from a dermatologist as the ground truth. The segmentation results were compared with other state-of-the-art methods along with the evaluation criteria. The unsupervised border detection system increased the true detection rate (TDR) is 4.31% and reduced the false positive rate (FPR) of 5.28%.

PMID: 20663582 [PubMed - as supplied by publisher]

Merkel cell polyomavirus is present in common warts and carcinoma in situ of the skin.

Fetched: August 4th, 2010, 9:26am CDT

Merkel cell polyomavirus is present in common warts and carcinoma in situ of the skin.

Hum Pathol. 2010 Jul 21;

Authors: Mertz KD, Pfaltz M, Junt T, Schmid M, Fernandez Figueras MT, Pfaltz K, Barghorn A, Kempf W

Polyomaviruses have been linked to diseases of immunosuppressed patients. We sought to determine the prevalence of Merkel cell polyomavirus in benign epithelial skin neoplasms and nonmelanoma skin cancer of immunosuppressed renal transplant recipients and long-term dialysis patients. Merkel cell polyomavirus DNA was detected by polymerase chain reaction (PCR) in 2 (10%) of 20 patients, in carcinomas in situ (Bowen's disease). In one of our patients with Merkel cell polyomavirus-positive carcinoma in situ, 9 (39.1%) of 23 skin lesions at various anatomical locations tested positive for Merkel cell polyomavirus sequences by PCR, including all of his common warts (4/4), half of his carcinoma in situ lesions (3/6), and 2 of his 3 seborrheic keratoses. In a second cohort of immunosuppressed renal transplant recipients, Merkel cell polyomavirus DNA was found in 1 (6.3%) of 16 common warts and in 2 (9.5%) of 21 carcinomas in situ. In immunocompetent individuals, Merkel cell polyomavirus DNA was found in 2 (6.7%) of 30 common warts and in 2 (8.3%) of 24 carcinomas in situ. DNA of other human polyomaviruses was not detected in any of the investigated skin neoplasms. We conclude that common warts and carcinomas in situ can be positive for Merkel cell polyomavirus in immunosuppressed as well as immunocompetent individuals. Remarkably, some of the Merkel cell polyomavirus-positive common warts did not contain human papillomavirus. Furthermore, Merkel cell polyomavirus can be found in various skin neoplasms of the same individual.

PMID: 20655089 [PubMed - as supplied by publisher]

Permalink for 'Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system.'

Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system.

Fetched: August 4th, 2010, 9:26am CDT

Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: Analysis of 5823 cases as the basis of the first consensus staging system.

J Am Acad Dermatol. 2010 Jun 18;

Authors: Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, Johnson TM, Liegeois-Kwon NJ, Otley CC, Paulson KG, Ross MI, Yu SS, Zeitouni NC, Byrd DR, Sondak VK, Gershenwald JE, Sober AJ, Nghiem P

BACKGROUND: The management of Merkel cell carcinoma (MCC) has been complicated by a lack of detailed prognostic data and by the presence of conflicting staging systems. OBJECTIVE: We sought to determine the prognostic significance of tumor size, clinical versus pathologic nodal evaluation, and extent of disease at presentation and thereby derive the first consensus staging/prognostic system for MCC. METHODS: A total of 5823 prospectively enrolled MCC cases from the National Cancer Data Base had follow-up data (median 64 months) and were used for prognostic analyses. RESULTS: At 5 years, overall survival was 40% and relative survival (compared with age- and sex-matched population data) was 54%. Among all MCC cases, 66% presented with local, 27% with nodal, and 7% with distant metastatic disease. For cases presenting with local disease only, smaller tumor size was associated with better survival (stage I, </=2 cm, 66% relative survival at 5 years; stage II, >2 cm, 51%; P < .0001). Patients with clinically local-only disease and pathologically proven negative nodes had better outcome (76% at 5 years) than those who only underwent clinical nodal evaluation (59%, P < .0001). LIMITATIONS: The National Cancer Data Base does not capture disease-specific survival. Overall survival for patients with MCC was therefore used to calculate relative survival based on matched population data. CONCLUSION: Although the majority (68%) of patients with MCC in this nationwide cohort did not undergo pathologic nodal evaluation, this procedure may be indicated in many cases as it improves prognostic accuracy and has important treatment implications for those found to have microscopic nodal involvement.

PMID: 20646783 [PubMed - as supplied by publisher]

Expression of stem cell markers nestin and cytokeratin 15 and 19 in cutaneous malignancies.

Fetched: August 4th, 2010, 9:26am CDT

Expression of stem cell markers nestin and cytokeratin 15 and 19 in cutaneous malignancies.

J Eur Acad Dermatol Venereol. 2010 Jul 12;

Authors: Abbas O, Bhawan J

Abstract Background Emerging evidence is implicating stem cells in the pathogenesis of different cutaneous neoplasms. The immunohistochemical use of stem cell markers has facilitated stem cell identification. While few studies have examined the expression of cytokertatin (CK)15 and cytokeratin (CK)19 in basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), only rarely have nestin expression been examined in these two malignancies. Furthermore, stem cell marker expression, to the best of our knowledge, has not been examined in Merkel cell carcinoma (MCC). Methods In this study, we examined the expression of stem cell markers CK15, CK19 and nestin in 51 overall cases (11 cases of MCC and 20 cases each of BCC and SCC) retrieved from the pathology files of Skin Pathology Laboratory, Boston University School of Medicine. Results Cytokeratin 15 immunoreactivity was observed in 30% of BCC cases and only a single (5%) SCC case, while all MCC cases were negative. While 60% of BCC cases and 30% of SCC cases stained positively with CK19, all MCC cases showed positive immunostaining in a dot-like pattern. While negative in BCC and MCC, nestin expression was interestingly seen in 45% of SCC cases. Conclusions Our study described the expression profiles of stem cell markers CK15, CK19 and nestin in BCC, SCC and MCC. In addition to confirming results of the previous reports, our study also showed positive nestin expression in around half of SCC cases, which adds this malignancy to the cutaneous tumours that have been so far reported to exhibit nestin expression.

PMID: 20629844 [PubMed - as supplied by publisher]

Merkel cell polyomavirus small T antigen mRNA level is increased following in vivo UV-radiation.

Fetched: August 4th, 2010, 9:26am CDT

Merkel cell polyomavirus small T antigen mRNA level is increased following in vivo UV-radiation.

PLoS One. 2010;5(7):e11423

Authors: Mogha A, Fautrel A, Mouchet N, Guo N, Corre S, Adamski H, Watier E, Misery L, Galibert MD

Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer involving Merkel cells. Recently, a new human polyomavirus was implicated in MCC, being present in 80% of the samples analyzed. In virus-positive MCC, the Merkel cell polyomavirus (MCPyV) is clonally integrated into the patients DNA, and carries mutations in its large T antigen, leading to a truncated protein. In non-symptomatic tissue MCPyV can reside at very low levels. MCC is also associated with older age, immunosuppression and sun exposure. However, the link with solar exposure remains unknown, as the precise mechanism and steps involved between time of infection by MCPyV and the development of MCC. We thus investigated the potential impact of solar simulated radiation (SSR) on MCPyV transcriptional activity. We screened skin samples of 20 healthy patients enrolled in a photodermatological protocol based on in vivo-administered 2 and 4 J/cm(2) SSR. Two patients were infected with two new variants of MCPyV, present in their episomal form and RT-QPCR analyses on SSR-irradiated skin samples showed a specific and unique dose-dependent increase of MCPyV small t antigen transcript. A luciferase based in vitro assay confirmed that small t promoter is indeed UV-inducible. These findings demonstrate that solar radiation has an impact on MCPyV mRNA levels that may explain the association between MCC and solar exposure.

PMID: 20625394 [PubMed - in process]

Distinction of 2 different primary Merkel cell carcinomas in 1 patient by Merkel cell polyomavirus genome analysis.

Fetched: August 4th, 2010, 9:26am CDT

Distinction of 2 different primary Merkel cell carcinomas in 1 patient by Merkel cell polyomavirus genome analysis.

Arch Dermatol. 2010 Jun;146(6):687-9

Authors: Schrama D, Thiemann A, Houben R, KÃ¤hler KC, Becker JC, Hauschild A

PMID: 20566946 [PubMed - indexed for MEDLINE]

Lack of evidence for direct involvement of Merkel cell polyomavirus (MCV) in chronic lymphocytic leukemia (CLL).

Fetched: August 4th, 2010, 9:26am CDT

Lack of evidence for direct involvement of Merkel cell polyomavirus (MCV) in chronic lymphocytic leukemia (CLL).

Blood. 2010 Jun 10;115(23):4973-4

Authors: Tolstov YL, Arora R, Scudiere SC, Busam K, Chaudhary PM, Chang Y, Moore PS

PMID: 20538816 [PubMed - indexed for MEDLINE]

Giant Merkel cell carcinoma of the left arm. Case report.

Fetched: August 4th, 2010, 9:26am CDT

Giant Merkel cell carcinoma of the left arm. Case report.

Ann Ital Chir. 2009 Nov-Dec;80(6):489-92

Authors: Sivelli R, Ghirarduzzi A, Del Rio P, Ricci R, Sianesi M

Merkel cell carcinoma is a rare tumor of dermal origin generally found in sun exposed skin. We report the case of a woman of 76 years old presenting a large vascularized Merkel cell carcinoma (MCC) of the left arm lateral to the elbow joint, infiltrating the muscolo-fascial plane who was treated with surgical therapy and post operative radiotherapy.

PMID: 20476686 [PubMed - indexed for MEDLINE]

New insights into merkel cell carcinoma.

Fetched: August 4th, 2010, 9:26am CDT

New insights into merkel cell carcinoma.

Adv Anat Pathol. 2010 May;17(3):155-61

Authors: Calder KB, Smoller BR

Merkel cell carcinoma (MCC) is a rare aggressive cutaneous malignancy of the elderly and immunocompromised populations. The clinical presentation of MCC is nonspecific, with the majority of cases presenting as localized skin involvement. Histologically and immunophenotypically, MCC is defined by both neuroendocrine and epithelial differentiation. Recently, the Merkel cell polyomavirus has been implicated in the pathogenesis of MCC. In addition, there have been numerous studies evaluating the histologic and immunohistochemical characteristics of MCC as they relate to diagnosis and prognosis. The purpose of this paper is to review the most salient and clinically relevant updates in the pathogenesis and histologic features of MCC. Specific attention is given to the clinical and histologic predictors of prognosis, staging, and the controversies concerning sentinel lymph node biopsy and therapy.

PMID: 20418670 [PubMed - indexed for MEDLINE]

Merkel cell carcinoma of the hand: case report and literature review.

Fetched: August 4th, 2010, 9:26am CDT

Merkel cell carcinoma of the hand: case report and literature review.

Chir Main. 2010 Apr;29(2):128-31

Authors: Daghistani W, Younan R, Brutus JP

We are reporting on a 72-year-old male who was diagnosed with Merkel cell carcinoma on the dorsal aspect of his left index finger. This rare highly aggressive malignancy of the skin has only exceptionally been described on the finger or hand. This case report helps review important findings associated with this rare malignancy and reviews the pertinent literature.

PMID: 20202882 [PubMed - indexed for MEDLINE]

Permalink for 'Expression of the tetraspanins CD9, CD37, CD63, and CD151 in Merkel cell carcinoma: strong evidence for a posttranscriptional fine-tuning of CD9 gene expression.'

Expression of the tetraspanins CD9, CD37, CD63, and CD151 in Merkel cell carcinoma: strong evidence for a posttranscriptional fine-tuning of CD9 gene expression.

Fetched: August 4th, 2010, 9:26am CDT

Expression of the tetraspanins CD9, CD37, CD63, and CD151 in Merkel cell carcinoma: strong evidence for a posttranscriptional fine-tuning of CD9 gene expression.

Mod Pathol. 2010 May;23(5):751-62

Authors: Woegerbauer M, Thurnher D, Houben R, Pammer J, Kloimstein P, Heiduschka G, Petzelbauer P, Erovic BM

Tetraspanins including CD9, CD37, CD63, and CD151 are linked to cellular adhesion, cell differentiation, migration, carcinogenesis, and tumor progression. The aim of the study was to detect, quantify, and evaluate the prognostic value of these tetraspanins in Merkel cell carcinoma and to study the regulation of CD9 mRNA expression in Merkel cell carcinoma cell lines in detail. Immunohistochemical staining of 28 Merkel cell carcinoma specimens from 25 patients showed a significant correlation of CD9 (P=0.03) and CD151 (P=0.043) expression to overall survival. CD9 and CD63 expression correlated significantly to patients' disease-free interval (P=0.017 and P=0.058). Of primary Merkel cell carcinoma tumors, 42% were CD9 positive in contrast to only 21% of the subcutaneous in-transit metastases. Characterization of the 5' untranslated region (UTR) of the CD9 mRNA from two cultured Merkel cell carcinoma cell lines revealed the presence of two major RNA species differing only in the length of their 5' termini (183 versus 102 nucleotides). In silico analysis of the long CD9 mRNA predicted a 5' UTR folding pattern blocking ribosomal scanning and translation. Quantitative data by real-time RT-PCR not only indicated a reduction of CD9 mRNA but also a distinct quantitative shift toward the long 5' UTR in CD9 receptor negative cells. These observations provide an example for a posttranscriptional fine-tuning of CD9 gene expression in tumor cells.

PMID: 20118909 [PubMed - indexed for MEDLINE]

Neuroendocrine cells and associated malignancies of the oral mucosa: a review.

Fetched: August 4th, 2010, 9:26am CDT

Neuroendocrine cells and associated malignancies of the oral mucosa: a review.

J Oral Pathol Med. 2010 Feb;39(2):121-7

Authors: Mahomed F

Neuroendocrine cells of the oral mucosa constitute an under-recognized component of the diffuse neuroendocrine system with diverse subpopulations and elusive biologic roles in the oral cavity. Primary malignant oral tumors that show a neuroendocrine phenotype display histomorphologic heterogeneity thereby giving rise to a spectrum of lesions in this rare category of oral malignancy. These lesions can be divided into neuroendocrine carcinomas (NECs) of small cell or non-small cell type. The former is further subdivided into the Merkel cell type or the pulmonary type while the latter includes atypical carcinoid tumor and large cell NEC. All histologic subtypes of oral NEC appear to have a strong predilection for men in their fifth or sixth decade and arise predominantly in the non-keratinized oral mucosa. The biologic behavior of oral Merkel cell carcinomas appears to be more aggressive than those of skin. It remains to be determined whether histologic categorization of the remaining tumor subtypes is predictive of patient survival in oral neuroendocrine tumors.

PMID: 20002872 [PubMed - indexed for MEDLINE]

Expression of hedgehog signaling molecules in Merkel cell carcinoma.

Fetched: August 4th, 2010, 9:26am CDT

Expression of hedgehog signaling molecules in Merkel cell carcinoma.

Head Neck. 2010 Mar;32(3):333-40

Authors: Brunner M, Thurnher D, Pammer J, Heiduschka G, Petzelbauer P, Schmid C, Schneider S, Erovic BM

BACKGROUND: The Hedgehog signaling pathway is important for human development and carcinogenesis in various malignancies. METHODS: One tissue microarray with triplets of 28 samples from 25 patients with Merkel cell carcinoma (MCC) was constructed. Six samples of normal skin and 5 samples of normal oral mucosa served as controls. All samples were analyzed immunohistochemically with antibodies directed against Sonic hedgehog, Indian hedgehog, Patched, Smoothened, Gli-1, Gli-2, and Gli-3. RESULTS: All investigated proteins were frequently and intensely overexpressed in MCCs (Sonic hedgehog, 93%; Indian hedgehog, 84%; Patched, 86%; Smoothened, 79%; Gli-1, 79%; Gli-2, 79%; Gli-3, 86%) compared with control samples. High levels of Patched and Indian hedgehog were significantly associated with an increase in patients overall (p = .015) and recurrence-free survival (p = .011), respectively. CONCLUSIONS: Our results indicate that the Hedgehog signaling pathway is strongly activated in MCC and thus may play a role in carcinogenesis.

PMID: 19644931 [PubMed - indexed for MEDLINE]

Spontaneous regression of Merkel cell carcinoma of the nose.

Fetched: August 4th, 2010, 9:26am CDT

Spontaneous regression of Merkel cell carcinoma of the nose.

Head Neck. 2010 Mar;32(3):411-4

Authors: Karkos PD, Sastry A, Hampal S, Al-Jafari M

BACKGROUND: Merkel Cell Carcinoma (MCC) is a rare neurendocrine tumor of cutaneous origin. METHODS AND RESULTS: A 79-year-old woman was seen with a neck lump and a lesion in the left nasal vestibule. Biopsy of the lesion revealed a primary neurendocrine MCC of the skin of the nasal vestibule with metastases to the cervical lymph nodes. The patient decided against any further active treatment. Follow-up of patient for 30 months showed spontaneous regression of the lesions without any active treatment. CONCLUSIONS: Although spontaneous resolution of MCC has been described for other head neck sites, there has not been any published case of nasal MCC regression. We present this rare case of nasal MCC with neck metastases and its regression.

PMID: 19373785 [PubMed - indexed for MEDLINE]

Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid.

Fetched: July 11th, 2010, 1:35pm CDT

Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid.

Virology. 2010 Sep 15;405(1):20-5

Authors: Pastrana DV, Pumphrey KA, Cuburu N, Schowalter RM, Buck CB

Merkel cell polyomavirus (MCV) has been implicated as a causative agent in Merkel cell carcinoma. Robust polyclonal antibody responses against MCV have been documented in human subjects, but monoclonal antibodies (mAbs) specific for the VP1 capsid protein have not yet been characterized. We generated 12 mAbs capable of binding recombinant MCV virus-like particles. The use of a short immunogenic priming schedule was important for production of the mAbs. Ten of the 12 mAbs were highly effective for immunofluorescent staining of cells expressing capsid proteins. An overlapping set of 10 mAbs were able to neutralize the infectivity of MCV-based reporter vectors, with 50% effective doses in the low picomolar range. Three mAbs interfered with the binding of MCV virus-like particles to cells. This panel of anti-capsid antibodies should provide a useful set of tools for the study of MCV.

PMID: 20598728 [PubMed - indexed for MEDLINE]

Permalink for 'Newly described human polyomaviruses Merkel Cell, KI and WU are present in urban sewage and may represent potential environmental contaminants.'

Newly described human polyomaviruses Merkel Cell, KI and WU are present in urban sewage and may represent potential environmental contaminants.

Fetched: July 11th, 2010, 1:35pm CDT

Newly described human polyomaviruses Merkel Cell, KI and WU are present in urban sewage and may represent potential environmental contaminants.

Virol J. 2010 Jun 28;7(1):141

Authors: Bofill-Mas S, Rodriguez-Manzano J, Calgua B, Carratala A, Girones R

ABSTRACT: Recently, three new polyomaviruses (KI, WU and Merkel cell polyomavirus) have been reported to infect humans. It has also been suggested that lymphotropic polyomavirus, a virus of simian origin, infects humans. KI and WU polyomaviruses have been detected mainly in specimens from the respiratory tract while Merkel cell polyomavirus has been described in a very high percentage of Merkel cell carcinomas. The distribution, excretion level and transmission routes of these viruses remain unknown. Here we analyzed the presence and characteristics of newly described human polyomaviruses in urban sewage and river water in order to assess the excretion level and the potential role of water as a route of transmission of these viruses. Nested-PCR assays were designed for the sensitive detection of the viruses studied and the amplicons obtained were confirmed by sequencing analysis. The viruses were concentrated following a methodology previously developed for the detection of JC and BK human polyomaviruses in environmental samples. JC polyomavirus and human adenoviruses were used as markers of human contamination in the samples. Merkel cell polyomavirus was detected in 7/8 urban sewage samples collected and in 2/7 river water samples. Also one urine sample from a pregnant woman, out of 4 samples analyzed, was positive for this virus. KI and WU polyomaviruses were identified in 1/8 and 2/8 sewage samples respectively. The viral strains detected were highly homologous with other strains reported from several other geographical areas. Lymphotropic polyomavirus was not detected in any of the 13 sewage neither in 9 biosolid/sludge samples analyzed. This is the first description of a virus isolated from sewage and river water with a strong association with cancer. Our data indicate that the Merkel cell polyomavirus is prevalent in the population and that it may be disseminated through the fecal/urine contamination of water. The procedure developed may constitute a useful tool for studying the excreted strains, prevalence and transmission of these recently described polyomaviruses.

PMID: 20584272 [PubMed - as supplied by publisher]

Permalink for 'Spontaneous regression in merkel cell carcinoma: report of two cases with a description of dermoscopic features and review of the literature.'

Spontaneous regression in merkel cell carcinoma: report of two cases with a description of dermoscopic features and review of the literature.

Fetched: July 11th, 2010, 1:35pm CDT

Spontaneous regression in merkel cell carcinoma: report of two cases with a description of dermoscopic features and review of the literature.

Dermatol Surg. 2010 May;36(5):687-93

Authors: Ciudad C, AvilÃ©s JA, Alfageme F, Lecona M, SuÃ¡rez R, LÃ¡zaro P

PMID: 20384741 [PubMed - indexed for MEDLINE]

Eyelid and periocular cutaneous Merkel cell carcinoma (aka. neuroendocrine or trabecular carcinoma).

Fetched: July 11th, 2010, 1:35pm CDT

Eyelid and periocular cutaneous Merkel cell carcinoma (aka. neuroendocrine or trabecular carcinoma).

Int Ophthalmol Clin. 2009;49(4):63-75

Authors: Barrett RV, Meyer DR

PMID: 20348858 [PubMed - indexed for MEDLINE]

Skin cancers associated with autoimmune conditions among elderly adults.

Fetched: June 26th, 2010, 9:50am CDT

Skin cancers associated with autoimmune conditions among elderly adults.

Br J Cancer. 2010 Jun 15;

Authors: Lanoy E, Engels EA

Background:Immunosuppression is a risk factor for certain skin cancers. Autoimmune conditions can involve the skin, and may involve immunosuppressive therapies.Methods:We conducted a population-based case-control study among elderly US adults using Surveillance, Epidemiology, and End Results-Medicare-linked data of 44 613 skin cancer cases and 178 452 frequency-matched controls. Medicare claims identified autoimmune conditions. Adjusted odds ratios (ORs) compared prevalence in cases and controls.Results:The most frequent autoimmune condition was rheumatoid arthritis (2.29%), which was associated with slightly increased risk of Merkel cell carcinoma (N=1977; OR (95%CI): 1.39 (1.10-1.74)). Risk of cutaneous non-Hodgkin's lymphoma (N=2652) was increased with psoriasis (OR (95%CI): 3.20 (2.62-3.92)). Risk of Kaposi's sarcoma (N=773) was elevated with ulcerative colitis (OR (95%CI): 2.76 (1.42-5.39)), and risk of other sarcomas (N=1324) was elevated with Graves disease (2.62 (1.30-5.31)).Conclusions:These findings suggest that immune disturbances in the skin, arising from autoimmune conditions or their treatment, promote development of skin cancer.British Journal of Cancer advance online publication, 15 June 2010; doi:10.1038/sj.bjc.6605733 www.bjcancer.com.

PMID: 20551958 [PubMed - as supplied by publisher]

Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin.

Fetched: June 26th, 2010, 9:50am CDT

Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin.

Cell Host Microbe. 2010 Jun 25;7(6):509-15

Authors: Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB

Mounting evidence indicates that Merkel cell polyomavirus (MCV), a circular double-stranded DNA virus, is a causal factor underlying a highly lethal form of skin cancer known as Merkel cell carcinoma. To explore the possibility that MCV and other polyomaviruses commonly inhabit healthy human skin, we developed an improved rolling circle amplification (RCA) technique to isolate circular DNA viral genomes from human skin swabs. Complete MCV genomes were recovered from 40% of healthy adult volunteers tested, providing full-length, apparently wild-type cloned MCV genomes. RCA analysis also identified two previously unknown polyomavirus species that we name human polyomavirus-6 (HPyV6) and HPyV7. Biochemical experiments show that polyomavirus DNA is shed from the skin in the form of assembled virions. A pilot serological study indicates that infection or coinfection with these three skin-tropic polyomaviruses is very common. Thus, at least three polyomavirus species are constituents of the human skin microbiome.

PMID: 20542254 [PubMed - in process]

Prevalence of Merkel cell Polyomavirus DNA in Cutaneous Lymphomas, Pseudolymphomas, and Inflammatory Skin Diseases.

Fetched: June 26th, 2010, 9:50am CDT

Prevalence of Merkel cell Polyomavirus DNA in Cutaneous Lymphomas, Pseudolymphomas, and Inflammatory Skin Diseases.

Am J Dermatopathol. 2010 Jun 9;

Authors: Andres C, Puchta U, Sander CA, Ruzicka T, Flaig MJ

Several groups confirmed Merkel cell polyomavirus (MCPyV) as the likely causative agent of Merkel cell carcinoma. Hematolymphoid disorders are known to be a substantial risk factor for Merkel cell carcinoma, and vice versa. The association between MCPyV and hematologic neoplasms is poorly analyzed, as well as the speculation that lymphocytes may serve as reservoir for MCPyV. Therefore, we investigated the prevalence of MCPyV DNA in primary cutaneous T- and B-cell lymphomas, pseudolymphomas (PLs), and inflammatory skin diseases with dominant lymphocytic infiltrate. We performed a molecular pathology study in 22 tissue samples and 1 blood sample of different cutaneous lymphomas from 19 patients (17 mature T-cell neoplasms, 5 mature B-cell neoplasms, and 1 immature hematopoietic malignancy), 13 PLs from 12 patients, and 25 various inflammatory skin diseases from 23 patients. All tumors were analyzed for the presence of MCPyV DNA by polymerase chain reaction, confirmed by Southern blot hybridization of polymerase chain reaction products. We detected MCPyV DNA in 4 of 23 (17.4%) cutaneous lymphoma tissue samples (3 of 17 mature T-cell neoplasms and 1 of 5 mature B-cell neoplasms), in 2 of 13 (15.4%) PL tissue samples, and 2 of 25 (8%) inflammatory skin conditions (1 drug reaction and 1 erythema multiforme). We conclude that MCPyV DNA is infrequently, but consistently present in lesional tissue from patients with primary cutaneous lymphomas, PLs, and inflammatory skin diseases; prevalence is in the range of 8%-17%. Our results suggest that MCPyV does not play a significant role in the pathogenesis of cutaneous lymphoproliferative disorders.

PMID: 20534985 [PubMed - as supplied by publisher]

[Reddish glassy tumor of the calf. Highly malignant]

Fetched: June 26th, 2010, 9:50am CDT

[Reddish glassy tumor of the calf. Highly malignant]

MMW Fortschr Med. 2010 Apr 15;152(15):5

Authors: Andres C, Flaig MJ, Belloni B

PMID: 20464858 [PubMed - indexed for MEDLINE]

Merkel cell carcinoma: selected clinical cases.

Fetched: June 26th, 2010, 9:50am CDT

Merkel cell carcinoma: selected clinical cases.

Curr Probl Cancer. 2010 Jan-Feb;34(1):118-23

Authors: Hamill JR, Messina JL

PMID: 20371079 [PubMed - indexed for MEDLINE]

Review of the role of radiation therapy in the management of Merkel cell carcinoma.

Fetched: June 26th, 2010, 9:50am CDT

Review of the role of radiation therapy in the management of Merkel cell carcinoma.

Curr Probl Cancer. 2010 Jan-Feb;34(1):108-17

Authors: Rao NG

PMID: 20371078 [PubMed - indexed for MEDLINE]

Systemic treatments for merkel cell carcinoma.

Fetched: June 26th, 2010, 9:50am CDT

Systemic treatments for merkel cell carcinoma.

Curr Probl Cancer. 2010 Jan-Feb;34(1):97-107

Authors: Kudchadkar R, Deconti R

PMID: 20371077 [PubMed - indexed for MEDLINE]

The surgical management of primary and metastatic Merkel cell carcinoma.

Fetched: June 26th, 2010, 9:50am CDT

The surgical management of primary and metastatic Merkel cell carcinoma.

Curr Probl Cancer. 2010 Jan-Feb;34(1):77-96

Authors: Gonzalez RJ, Padhya TA, Cherpelis BS, Prince MD, Aya-Ay ML, Sondak VK, Cruse CW, Zager JS

PMID: 20371076 [PubMed - indexed for MEDLINE]

Imaging of Merkel cell carcinoma.

Fetched: June 26th, 2010, 9:50am CDT

Imaging of Merkel cell carcinoma.

Curr Probl Cancer. 2010 Jan-Feb;34(1):65-76

Authors: Zager JS, Brodsky S, Berman CG

PMID: 20371075 [PubMed - indexed for MEDLINE]

Merkel cell carcinoma: pathologic findings and prognostic factors.

Fetched: June 26th, 2010, 9:50am CDT

Merkel cell carcinoma: pathologic findings and prognostic factors.

Curr Probl Cancer. 2010 Jan-Feb;34(1):47-64

Authors: McCardle TW, Sondak VK, Zager J, Messina JL

PMID: 20371074 [PubMed - indexed for MEDLINE]

Clinical recognition, diagnosis, and staging of merkel cell carcinoma, and the role of the multidisciplinary management team.

Fetched: June 26th, 2010, 9:50am CDT

Clinical recognition, diagnosis, and staging of merkel cell carcinoma, and the role of the multidisciplinary management team.

Curr Probl Cancer. 2010 Jan-Feb;34(1):38-46

Authors: Sarnaik AA, Lien MH, Nghiem P, Bichakjian CK

PMID: 20371073 [PubMed - indexed for MEDLINE]

The etiology and epidemiology of merkel cell carcinoma.

Fetched: June 26th, 2010, 9:50am CDT

The etiology and epidemiology of merkel cell carcinoma.

Curr Probl Cancer. 2010 Jan-Feb;34(1):14-37

Authors: Agelli M, Clegg LX, Becker JC, Rollison DE

PMID: 20371072 [PubMed - indexed for MEDLINE]

Foreword. Merkel cell carcinoma.

Fetched: June 26th, 2010, 9:50am CDT

Foreword. Merkel cell carcinoma.

Curr Probl Cancer. 2010 Jan-Feb;34(1):13

Authors: Delman KA

PMID: 20371071 [PubMed - indexed for MEDLINE]

Merkel cell polyomavirus in cutaneous swabs.

Fetched: June 26th, 2010, 9:50am CDT

Merkel cell polyomavirus in cutaneous swabs.

Emerg Infect Dis. 2010 Apr;16(4):685-7

Authors: Foulongne V, Kluger N, Dereure O, Mercier G, MolÃ¨s JP, Guillot B, Segondy M

To assess the usefulness of using cutaneous swabs to detect Merkel cell polyomavirus (MCPyV) DNA, we analyzed swabs from persons with Merkel cell carcinoma (MCC), others with skin diseases, and healthy volunteers. MCPyV was detected in at least 1 sample from virtually all participants. Viral loads were higher in samples from patients with MCC.

PMID: 20350388 [PubMed - indexed for MEDLINE]

Human polyoma viruses and disease with emphasis on clinical BK and JC.

Fetched: June 26th, 2010, 9:50am CDT

Human polyoma viruses and disease with emphasis on clinical BK and JC.

J Clin Virol. 2010 Apr;47(4):306-12

Authors: Boothpur R, Brennan DC

Polyoma viruses are ubiquitous infecting many different mammalian species including humans. There are five known human polyoma viruses. JC virus and BK virus are two polyoma viruses identified nearly three decades ago. Recently WU, KI and Merkel cell polyoma viruses have been isolated from humans. The exact role of these three newly discovered viruses in human disease is not known. Most human polyoma disease is caused by BK and JC viruses which are usually acquired in childhood. Approximately 50-80% of humans have seropositivity to these viruses. Clinically apparent diseases in immunocompetent hosts are extremely rare. These viruses remain latent possibly in the lymphoid organs, neuronal tissue, and kidney and under the circumstances of severe immunosuppression both these viruses reactivate. Neurotropic JC virus reaches the brain and causes progressive multifocal leukoencephalopathy, a demyelinating disease of the central nervous system with a high mortality rate. BK virus is urotheliotropic and its reactivation causes a form of interstitial nephritis, known as BK or polyoma virus associated nephropathy which is associated with high graft loss if not recognized early. There are no known effective antiviral agents for any of the polyoma viruses.

PMID: 20060360 [PubMed - indexed for MEDLINE]

[Young patient with eyelid Merkel carcinoma: Mohs microsurgery versus exenteration]

Fetched: June 26th, 2010, 9:50am CDT

[Young patient with eyelid Merkel carcinoma: Mohs microsurgery versus exenteration]

Arch Soc Esp Oftalmol. 2009 Nov;84(11):581-4

Authors: RodrÃguez-Prieto MA, Alonso-Alonso T, Toribio-GarcÃa JA, Mateos-HernÃ¡ndez A

CASE REPORT: We present the case of a 47-year-old female suffering from progeria who developed an eyelid Merkel cell carcinoma (MCC) following cyclosporine treatment for a corneal transplant. She underwent excision of the lesion by Mohs micrographic surgery (MMS) and received adjuvant treatment with radiotherapy. Later she had a recurrent tumour for which a wide excision with orbital exenteration was performed. The patient was fit and well at the 24-month follow-up. DISCUSSION: MCC is an aggressive tumour that has a larger incidence in elderly people, women and immunosuppressed patients. Our approach with the patient must be global, avoiding risk factors in predisposed subjects. MMS seems unsuitable for the treatment of MCC; if tumour recurrence occurs a wide resection should be performed (Arch Soc Esp Oftalmol 2009; 84: 581-584).

PMID: 19967613 [PubMed - indexed for MEDLINE]

Pituitary metastasis of Merkel cell carcinoma.

Fetched: June 26th, 2010, 9:50am CDT

Pituitary metastasis of Merkel cell carcinoma.

J Neurooncol. 2010 Apr;97(2):295-9

Authors: Feletti A, Marton E, Rossi S, Canal F, Longatti P, Billeci D

Merkel cell carcinoma (MCC) is a malignant neuroendocrine tumor of the skin that demonstrates a remarkable tendency to metastasize. However, only a few cases of MCC brain metastases have been reported in the literature. We here present a unique case of a pituitary metastasis of MCC in a 65-year-old patient with a history of pituitary adenoma. This case is particularly novel due to the fact that the primary site of the MCC is unknown.

PMID: 19806319 [PubMed - indexed for MEDLINE]

A guide to keeping teenagers alive - Chicago Daily Herald

Posted: August 30th, 2010, 10:14pm CDT

A guide to keeping teenagers alive
Chicago Daily Herald
Vasquez's lengthy imprisonment won't bring back any of the teenagers she drove to their deaths: Katie Merkel, 14; James McGee, 14; Jessica Nutoni, 15; ...

Denglish anyone? - Malaysia Star

Posted: August 27th, 2010, 5:22pm CDT

Malaysia Star

Denglish anyone?
Malaysia Star
German Chancellor Angela Merkel seems to be saying to British Prime Minister David Cameron. — AP PHOTO Working as a freelance editor, I am confronted with ...

Beijing's High-Tech Ambitions - The Dangers Of Germany's Dependence On China - Free Internet Press

Posted: August 27th, 2010, 1:44pm CDT

Beijing's High-Tech Ambitions - The Dangers Of Germany's Dependence On China
Free Internet Press
It's a humid Friday afternoon in Beijing, where German Chancellor Angela Merkel is addressing a friendly crowd of 80 students from the Central Party School, ...

and more »

Mom of 2 faces 28 years for fatal 2007 crash - ABC7Chicago.com

Posted: August 27th, 2010, 6:56am CDT

Mom of 2 faces 28 years for fatal 2007 crash
ABC7Chicago.com
Teens Katherine Merkel, Tiffany Urso, Jessica Nutoni, Matthew Frank and James McGee were killed. Vasquez and the three surviving teenagers were seriously ...

and more »

Town Talk: Week of Aug. 25 - SuburbanJournals

Posted: August 24th, 2010, 12:29pm CDT

Town Talk: Week of Aug. 25
SuburbanJournals
I just called to see, where is Merkel? Editor's Note: Jim Merkel has moved the Illinois office of the Suburban Journals. Readers who want to continue to ...

and more »

ImmonoGen Drug Gets Orphan Status - InvestorIdeas.com (press release) (blog)

Posted: August 24th, 2010, 11:12am CDT

ImmonoGen Drug Gets Orphan Status
InvestorIdeas.com (press release) (blog)
... has orphan drug status in the United States and the European Union (EU) for the treatment of Merkel cell carcinoma, which is a kind of skin cancer. ...

and more »

ImmonoGen Drug Gets Orphan Status - Daily Markets

Posted: August 24th, 2010, 11:10am CDT

ImmonoGen Drug Gets Orphan Status
Daily Markets
... has orphan drug status in the United States and the European Union (EU) for the treatment of Merkel cell carcinoma, which is a kind of skin cancer. ...

and more »

ImmonoGen Drug Gets Orphan Status - Zacks.com

Posted: August 24th, 2010, 10:44am CDT

ImmonoGen Drug Gets Orphan Status
Zacks.com
... has orphan drug status in the United States and the European Union (EU) for the treatment of Merkel cell carcinoma, which is a kind of skin cancer. ...

and more »

ImmunoGen, Inc. Announces Orphan Drug Designation Granted To Lorvotuzumab ... - Medical News Today (press release)

Posted: August 20th, 2010, 1:16am CDT

ImmunoGen, Inc. Announces Orphan Drug Designation Granted To Lorvotuzumab ...
Medical News Today (press release)
CD56 is expressed on SCLC, Merkel cell carcinoma, ovarian cancer, carcinoid and other solid tumors of neuroendocrine origin, and lorvotuzumab mertansine is ...

and more »

Most Likely to See Basal Cell Carcinoma Return with Red Hair, More Education ... - SeniorJournal.com

Posted: August 16th, 2010, 2:33pm CDT

SeniorJournal.com

Most Likely to See Basal Cell Carcinoma Return with Red Hair, More Education ...
SeniorJournal.com
Other nonmelanoma skin cancers are Kaposi's sarcoma, Merkel cell carcinoma, and cutaneous lymphoma. Skin cancer is the most common form of cancer in the ...

and more »

Market Watch - The Hospitalist Online

Posted: August 12th, 2010, 8:45am CDT

Market Watch
The Hospitalist Online
IMGN910 has received orphan drug status for treating Merkel cell carcinoma, a skin cancer that usually occurs on the head or neck. ...

Invited Commentary - Archives of Internal Medicine

Posted: August 9th, 2010, 1:18pm CDT

Invited Commentary
Archives of Internal Medicine
For instance, Merkel cell carcinoma incidence is dramatically increased in persons infected with HIV, 7 but the total number of cases worldwide is so low ...

and more »

Teacher concludes personal journey - Ultimate Memorial (blog)

Posted: August 5th, 2010, 3:56pm CDT

Teacher concludes personal journey
Ultimate Memorial (blog)
A biopsy discovered he had merkel cell carcinoma, a rare form of skin cancer that usually attacks fair-skinned males over 65. The disease has the potential ...

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results - PharmaLive.com (press release)

Posted: August 5th, 2010, 11:39am CDT

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results
PharmaLive.com (press release)
... 2010 from a trial assessing this compound for the treatment of advanced small-cell lung cancer (SCLC), Merkel cell carcinoma (MCC) and ovarian cancer. ...

and more »

ImmunoGen sees sharp revenue drop for fiscal 2010 - Mass High Tech

Posted: August 5th, 2010, 6:26am CDT

ImmunoGen sees sharp revenue drop for fiscal 2010
Mass High Tech
... drug status from both the FDA and the EU Committee for Orphan Medicinal Products for the compound IMGN901 to be used to treat Merkel cell carcinoma. ...

and more »

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million - News-Medical.net

Posted: August 5th, 2010, 12:03am CDT

ImmunoGen fourth-quarter 2010 net loss increases to $13.4 million
News-Medical.net
... 2010 from a trial assessing this compound for the treatment of advanced small-cell lung cancer (SCLC), Merkel cell carcinoma (MCC) and ovarian cancer. ...

and more »

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results - Bradenton Herald

Posted: August 4th, 2010, 2:21pm CDT

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results
Bradenton Herald
... 2010 from a trial assessing this compound for the treatment of advanced small-cell lung cancer (SCLC), Merkel cell carcinoma (MCC) and ovarian cancer. ...

and more »

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results - SunHerald.com

Posted: August 4th, 2010, 2:11pm CDT

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results
SunHerald.com
... 2010 from a trial assessing this compound for the treatment of advanced small-cell lung cancer (SCLC), Merkel cell carcinoma (MCC) and ovarian cancer. ...

and more »

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results - FierceBiotech

Posted: August 4th, 2010, 2:03pm CDT

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results
FierceBiotech
... 2010 from a trial assessing this compound for the treatment of advanced small-cell lung cancer (SCLC), Merkel cell carcinoma (MCC) and ovarian cancer. ...

and more »

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results - Benzinga

Posted: August 4th, 2010, 1:48pm CDT

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results
Benzinga
... 2010 from a trial assessing this compound for the treatment of advanced small-cell lung cancer (SCLC), Merkel cell carcinoma (MCC) and ovarian cancer. ...

and more »

ImmunoGen, Inc. Reports Fourth Quarter And Fiscal Year 2010 Financial Results - TheStreet.com

Posted: August 4th, 2010, 1:16pm CDT

ImmunoGen, Inc. Reports Fourth Quarter And Fiscal Year 2010 Financial Results
TheStreet.com
... 2010 from a trial assessing this compound for the treatment of advanced small-cell lung cancer (SCLC), Merkel cell carcinoma (MCC) and ovarian cancer. ...

and more »

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results - Trading Markets (press release)

Posted: August 4th, 2010, 1:14pm CDT

ImmunoGen, Inc. Reports Fourth Quarter and Fiscal Year 2010 Financial Results
Trading Markets (press release)
... 2010 from a trial assessing this compound for the treatment of advanced small-cell lung cancer (SCLC), Merkel cell carcinoma (MCC) and ovarian cancer. ...

and more »

Support comes in droves for Sgt. Carter - Martinez News-Gazette

Posted: August 2nd, 2010, 10:29am CDT

Support comes in droves for Sgt. Carter
Martinez News-Gazette
For ticket information, contact Irene Merkel at 925-372-3443 and for raffle donations contact Robin Gonzales at 925-372-3460. If you would like to make a ...

and more »

Germany: memorial service for Love Parade victims - Washington Times

Posted: August 1st, 2010, 7:08pm CDT

Washington Times

Germany: memorial service for Love Parade victims
Washington Times
Among those at Salvator church were German Chancellor Angela Merkel, President Christian Wulff, family members of the victims and many relief workers who ...

and more »

Germany: memorial service for Love Parade victims - Daily Caller

Posted: August 1st, 2010, 2:55pm CDT

Germany: memorial service for Love Parade victims
Daily Caller
Among those at Salvator church were German Chancellor Angela Merkel, President Christian Wulff, family members of the victims and many relief workers who ...

and more »

Germany: memorial service for Love Parade victims - NOLA.com

Posted: August 1st, 2010, 9:41am CDT

Germany: memorial service for Love Parade victims
NOLA.com
Chancellor Angela Merkel and President Christian Wulff were at the event. Family members of the victims also attended. The 21 people who died were aged 18 ...

and more »

Germany: memorial service for Love Parade victims - Lansdale Reporter

Posted: August 1st, 2010, 6:53am CDT

Germany: memorial service for Love Parade victims
Lansdale Reporter
Among those at Salvator church were German Chancellor Angela Merkel, President Christian Wulff, family members of the victims and many relief workers who ...

and more »

Service remembers Love Parade dead - TheNewsTribune.com

Posted: August 1st, 2010, 12:37am CDT

Service remembers Love Parade dead
TheNewsTribune.com
Among those at Salvator church were German Chancellor Angela Merkel, President Christian Wulff, family members of the victims, and many relief workers who ...

and more »

Germany: memorial service for Love Parade victims - WTNH

Posted: July 31st, 2010, 7:09pm CDT

WTNH	Germany: memorial service for Love Parade victims WTNH Among those at Salvator church were German Chancellor Angela Merkel, President Christian Wulff, family members of the victims and many relief workers who ... and more »

Germany: memorial service for Love Parade victims - WTHI

Posted: July 31st, 2010, 7:04pm CDT

WTHI	Germany: memorial service for Love Parade victims WTHI Among those at Salvator church were German Chancellor Angela Merkel, President Christian Wulff, family members of the victims and many relief workers who ... and more »

Germany: memorial service for Love Parade victims - WAVY-TV

Posted: July 31st, 2010, 6:58pm CDT

WAVY-TV

Germany: memorial service for Love Parade victims
WAVY-TV
Among those at Salvator church were German Chancellor Angela Merkel, President Christian Wulff, family members of the victims and many relief workers who ...

and more »

Germany: memorial service for Love Parade victims - Providence Eyewitness News

Posted: July 31st, 2010, 6:57pm CDT

Providence Eyewitness News

Germany: memorial service for Love Parade victims
Providence Eyewitness News
Among those at Salvator church were German Chancellor Angela Merkel, President Christian Wulff, family members of the victims and many relief workers who ...

and more »

Germany's Gift to Obama: Taking in Two Guantánamo Inmates - TIME

Posted: July 8th, 2010, 3:45pm CDT

Germany's Gift to Obama: Taking in Two Guantánamo Inmates
TIME
In 2006, the Bush Administration asked Chancellor Angela Merkel's government to accept a group of Uighur detainees from Guantánamo. ...

and more »

George Sherman Richards - Mansfield News Journal

Posted: July 8th, 2010, 4:03am CDT

George Sherman Richards
Mansfield News Journal
In late January 2010, he came to Houston seeking treatment for Merkel cell carcinoma at MD Anderson. He soon found a "pad" at MainStay Suites near the ...

Germans accept two detainees from Gitmo - Gulf Times

Posted: July 7th, 2010, 1:22pm CDT

Germans accept two detainees from Gitmo
Gulf Times
Interior Minister Thomas de Maiziere said Chancellor Angela Merkel's administration and state governments, whose cooperation is needed in settling the men ...

Germany to accept two Guantanamo detainees - France24

Posted: July 7th, 2010, 10:39am CDT

France24

Germany to accept two Guantanamo detainees
France24
Interior Minister Thomas de Maiziere said Chancellor Angela Merkel's administration and state governments, whose cooperation is needed in settling the men ...

Germany to accept two Guantanamo detainees - Tolerance

Posted: July 7th, 2010, 10:36am CDT

Tolerance

Germany to accept two Guantanamo detainees
Tolerance
Interior Minister Thomas de Maiziere said Chancellor Angela Merkel's administration and state governments, whose cooperation is needed in settling the men ...

Germany to accept two Guantanamo detainees - Radio Netherlands

Posted: July 7th, 2010, 10:35am CDT

Germany to accept two Guantanamo detainees
Radio Netherlands
Interior Minister Thomas de Maiziere said Chancellor Angela Merkel's administration and state governments, whose cooperation is needed in settling the men ...

Germany to accept two Guantanamo detainees - AFP

Posted: July 7th, 2010, 10:31am CDT

AFP	Germany to accept two Guantanamo detainees AFP Interior Minister Thomas de Maiziere said Chancellor Angela Merkel's administration and state governments, whose cooperation is needed in settling the men ...

Germany to accept two Guantanamo detainees - Raw Story

Posted: July 7th, 2010, 10:29am CDT

Germany to accept two Guantanamo detainees
Raw Story
Interior Minister Thomas de Maiziere said Chancellor Angela Merkel's administration and state governments, whose cooperation is needed in settling the men ...

Buzzards Bay man charged in baseball bat attack - Cape Cod Times

Posted: July 7th, 2010, 11:23pm CDT

Buzzards Bay man charged in baseball bat attack
Cape Cod Times
Merkel told police he had the bat because he was using it to search through some nearby bushes, where the man had thrown Merkel's cell phone during the ...

and more »

Buzzards Bay man held on $5K bail - Cape Cod Times

Posted: July 6th, 2010, 2:11pm CDT

Buzzards Bay man held on $5K bail
Cape Cod Times
Merkel told police he had the bat because he was using it to search through some nearby bushes, where the man had thrown Merkel's cell phone during the ...

and more »

Shrewsbury girl on a lifesaving mission - Community Advocate

Posted: June 23rd, 2010, 11:02am CDT

Shrewsbury girl on a lifesaving mission
Community Advocate
Jessica Sebring, 16, of Shrewsbury presents a check for $30000 for Dr. Wang's Merkel Cell Carcinoma research in memory of ...

Al Copeland park: Dream or nightmare? - NOLA.com

Posted: June 20th, 2010, 10:29am CDT

NOLA.com

Al Copeland park: Dream or nightmare?
NOLA.com
The family has formed a foundation to fight Merkel cell carcinoma, the rare cancer that took the life of the Copeland family patriarch. ...

Accountability for Torture: Europe Vs. United States - Huffington Post (blog)

Posted: June 15th, 2010, 9:26am CDT

Accountability for Torture: Europe Vs. United States
Huffington Post (blog)
In 2005, German Chancellor Angela Merkel stated at a press conference -- with then-Secretary of State Condoleezza Rice standing by her side -- that the ...

and more »

German government still leaning towards same FIT cut - Digitimes

Posted: June 14th, 2010, 9:45pm CDT

German government still leaning towards same FIT cut
Digitimes
Though delayed, the odds of the original subsidy cut, with the support of German Chancellor Angela Merkel, passing a second vote have greatly increased, ...

and more »

Taylor County Sheriff's Office: Pregnant teen reportedly 'trampled' - Abilene Reporter-News

Posted: June 14th, 2010, 12:16pm CDT

Taylor County Sheriff's Office: Pregnant teen reportedly 'trampled'
Abilene Reporter-News
06/14 2:16 AM – Young child called from a residence south of Merkel, stating parents were fighting and his father was hitting his mother. ...

Has Christian Democracy Reached A Dead End In Europe? - Theos

Posted: June 10th, 2010, 6:51am CDT

Has Christian Democracy Reached A Dead End In Europe?
Theos
... at Merkel – a divorced, childless Protestant – saying that many of her policies (on stem cell research, for instance) had no grounding in Christianity. ...

and more »

Has Christian Democracy reached a dead end in Europe? - U.TV

Posted: June 10th, 2010, 3:16am CDT

Has Christian Democracy reached a dead end in Europe?
U.TV
... had already been sniping at Merkel – a divorced, childless Protestant – from the sidelines, saying that many of her policies (on stem cell research, ...

and more »

Has Christian Democracy reached a dead end in Europe? - The Guardian

Posted: June 10th, 2010, 3:00am CDT

Has Christian Democracy reached a dead end in Europe?
The Guardian
... at Merkel – a divorced, childless Protestant – saying that many of her policies (on stem cell research, for instance) had no grounding in Christianity. ...

and more »

Permalink for 'Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy'

Epidemiological Registry Describing Treatment Reality and Therapy Modalities of Patients With Lung Cancer (NSCLC, SCLC and Neuroendocrine Tumors) Requiring Therapy

Posted: August 30th, 2010, 9:00am CDT

Conditions: Observational Study; Registry
Intervention:
Sponsor: iOMEDICO AG
Recruiting - verified August 2010

A Study of PNT2258 in Patients With Advanced Solid Tumors

Posted: August 27th, 2010, 9:00am CDT

Conditions: Oncology; Lymphoma; Prostate; Melanoma
Intervention: Drug: PNT2258
Sponsor: Pronai Therapeutics, Inc
Recruiting - verified August 2010

Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma

Posted: August 27th, 2010, 9:00am CDT

Condition: Metastatic Melanoma
Intervention: Drug: Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Recruiting - verified August 2010

Evaluation of a Simulation Training Tool to Identify Lesions Requiring Further Screening for Melanoma

Posted: August 27th, 2010, 9:00am CDT

Conditions: Skin Simulation Model; Mastery Learning Model to Simulation Training for Visual Screening for Melanoma and Skin Biopsy
Intervention: Other: Simulation teaching session
Sponsor: Northwestern University
Recruiting - verified August 2010

IL15 Dendritic Cell Vaccine for Patients With Resected Stage IIIc and Stage IV Melanoma

Posted: August 25th, 2010, 9:00am CDT

Condition: Stage IIIc/IV Melanoma
Intervention: Biological: Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand
Sponsors: Baylor Research Institute; National Institutes of Health (NIH); National Cancer Institute (NCI)
Not yet recruiting - verified August 2010

Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

Posted: August 23rd, 2010, 9:00am CDT

Conditions: Lung Cancer; Lung Cancer Non-Small Cell Cancer (NSCLC); Lung Cancer Small Cell Lung Cancer (SCLC); Mesothelioma
Interventions: Procedure: Stereotactic Body Radiation Therapy (SBRT); Drug: Iohexol
Sponsor: Stanford University
Recruiting - verified August 2010

Trial of Surgical Excision Margins in Thick Primary Melanoma

Posted: August 17th, 2010, 9:00am CDT

Conditions: Melanoma; Surgery; Treatment Outcome
Interventions: Procedure: 2-cm margin; Procedure: 4-cm margin
Sponsors: Karolinska Institutet; Swedish Cancer Society; Stockholm Cancer Society
Completed - verified June 1991

Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation

Posted: August 12th, 2010, 9:00am CDT

Conditions: Lung Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer
Intervention: Procedure: Exhaled Breath Sampling
Sponsor: Stanford University
Recruiting - verified August 2010

The Effect of Adding Intraoperative Regional Anesthesia on Cancer Recurrence in Patients Undergoing Lung Cancer Resection

Posted: August 10th, 2010, 9:00am CDT

Condition: Lung Cancer
Interventions: Other: General-epidural anesthesia and analgesia; Other: Balanced general anesthesia and postoperative opioids
Sponsor: Outcomes Research Consortium
Recruiting - verified August 2010

Permalink for 'Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery'

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Posted: August 5th, 2010, 9:00am CDT

Condition: Melanoma (Skin)
Interventions: Biological: MART-1:26-35(27L) peptide vaccine; Biological: NY-ESO-1 peptide vaccine; Biological: anti-PD-1 human monoclonal antibody MDX-1106; Biological: gp100:209-217(210M) peptide vaccine; Biological: gp100:280-288(288V) peptide vaccine; Drug: Montanide ISA 51 VG; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2010

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Stage IV Melanoma That Has Been Removed By Surgery

Posted: August 5th, 2010, 9:00am CDT

Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor

Posted: August 2nd, 2010, 9:00am CDT

Conditions: Neuroendocrine Tumors; Carcinoid Tumor
Intervention: Drug: RAD001 (everolimus, Afinitor®)
Sponsors: Guangdong General Hospital; Novartis
Active, not recruiting - verified May 2010

Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors

Posted: August 2nd, 2010, 9:00am CDT

Condition: Metastatic Liver Disease
Intervention: Device: TheraSphere, Yttrium-90 glass Microspheres
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Not yet recruiting - verified August 2010

$Permalink for 'Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer'$

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Posted: July 29th, 2010, 9:00am CDT

Condition: Small Cell Lung Cancer
Intervention: Drug: STA-9090
Sponsors: Dana-Farber Cancer Institute; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Synta Pharmaceuticals Corp.
Recruiting - verified July 2010

Study of Panitumumab in the Treatment of Carcinoid Syndrome

Posted: July 28th, 2010, 9:00am CDT

Condition: Carcinoid Syndrome
Intervention: Drug: Panitumumab
Sponsors: Boston Medical Center; Amgen
Not yet recruiting - verified July 2010

A Two Arm Trial of Axitinib and Carboplatin/Paclitaxel in Melanoma (CC# 10852)

Posted: July 28th, 2010, 9:00am CDT

Condition: Melanoma
Intervention:
Sponsor: University of California, San Francisco
Recruiting - verified July 2010

Circulating Tumor Cells (CTCs) as a Blood-based Tumor Marker in Patients With Small Cell Lung Cancer (SCLC)

Posted: July 27th, 2010, 9:00am CDT

Condition: Small Cell Lung Cancer
Intervention: Other: Blood sample collection
Sponsors: University of Kansas; Department of Veterans Affairs; University of Pennsylvania; Coney Island Hospital, Brooklyn, NY; University of Nebraska
Recruiting - verified July 2010

Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)

Posted: July 21st, 2010, 9:00am CDT

Conditions: Pancreas; Neuroendocrine
Intervention: Drug: MK-2206
Sponsors: Memorial Sloan-Kettering Cancer Center; Merck
Recruiting - verified July 2010

Early Diagnosis of Malignant Transformation of Pigmentary Skin Lesions

Posted: July 21st, 2010, 9:00am CDT

Conditions: Malignant Melanoma; Pigmented Nevi; Skin Neoplasm
Intervention:
Sponsor: Hadassah Medical Organization
Recruiting - verified July 2010

Permalink for 'Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification'

Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas , Stage III Unresectable Melanomas, or Stage IV Melanomas With c-KIT Mutation or Amplification

Posted: July 21st, 2010, 9:00am CDT

Conditions: Primary Melanomas,; Stage III Unresectable Melanomas,; or Stage IV Melanomas With c-KIT Mutation; or Amplification.
Intervention: Drug: Nilotinib
Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting - verified August 2010

Permalink for 'Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)'

Concurrent Chemo-radiotherapy With Intensity-Modulated Radiation Therapy (IMRT) for Limited Disease Small Cell Lung Cancer (LD-SCLC)

Posted: July 19th, 2010, 9:00am CDT

Condition: Stage I-III Small Cell Lung Cancer
Intervention: Radiation: Radiotherapy
Sponsor: Maastricht Radiation Oncology
Recruiting - verified July 2010

$Permalink for 'Hypofractionated Proton Radiation Therapy'$

Hypofractionated Proton Radiation Therapy

Posted: July 16th, 2010, 9:00am CDT

Conditions: Non-small Cell Lung Cancer; Small Cell Lung Cancer; Carcinoid; Thymic Cancer; Lung Cancer
Intervention: Radiation: Proton Therapy
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified July 2010

A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma

Posted: July 16th, 2010, 9:00am CDT

Condition: Malignant Melanoma
Intervention: Drug: RO5185426
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010

Permalink for 'Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer'

Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer

Posted: July 16th, 2010, 9:00am CDT

Condition: Small Cell Lung Carcinoma
Interventions: Drug: Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed; Drug: Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed
Sponsor: Bayer
Recruiting - verified August 2010

Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies

Posted: July 14th, 2010, 9:00am CDT

Conditions: Neuroendocrine Tumors; Brain (Nervous System) Cancers; Colon/Rectal Cancer; Colon/Rectal Cancer Colon Cancer; Hepatobiliary Cancers; Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma); Hepatobiliary Cancers Liver
Intervention: Procedure: CT perfusion
Sponsors: Stanford University; Siemens Healthcare Sector; GE Healthcare
Not yet recruiting - verified July 2010

$Permalink for '131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma'$

131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Pheochromocytoma

Posted: July 13th, 2010, 9:00am CDT

Conditions: Refractory Neuroblastoma; Metastatic Pheochromocytoma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG); Drug: 131 I-MIBG
Sponsor: Children's Hospital of Philadelphia
Recruiting - verified July 2010

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Posted: July 12th, 2010, 9:00am CDT

Condition: Melanoma
Interventions: Drug: CCI-779; Drug: AZD6244
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified July 2010

Panobinostat, Etoposide, and Cisplatin as First-Line Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Posted: July 9th, 2010, 9:00am CDT

Condition: Lung Cancer
Interventions: Drug: cisplatin; Drug: etoposide phosphate; Drug: panobinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsor: All Ireland Cooperative Oncology Research Group
Recruiting - verified July 2010

Permalink for 'Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer'

Phase II Study of Aldesleukin (IL-2) Following the Administration of Zanolimumab (Anti-CD4mAb) in Metastatic Melanoma and Metastatic Renal Cancer

Posted: July 9th, 2010, 9:00am CDT

Conditions: Metastatic Melanoma; Metastatic Renal Cancer
Interventions: Drug: Zanolimumab; Drug: Aldesleukin
Sponsor: National Cancer Institute (NCI)
Recruiting - verified June 2010

Permalink for 'Study of Sorafenib Maintenance in Patients With Extensive Disease Small Cell Lung Cancer ED-SCLC After Response to Induction Chemotherapy'

Study of Sorafenib Maintenance in Patients With Extensive Disease Small Cell Lung Cancer ED-SCLC After Response to Induction Chemotherapy

Posted: July 8th, 2010, 9:00am CDT

Condition: Small Cell Lung Cancer
Intervention: Drug: Sorafenib
Sponsors: National Cancer Center, Korea; Bayer
Not yet recruiting - verified July 2010

A Study of Avastin (Bevacizumab) in Combination With Dacarbazine in Patients With Unresectable/Metastatic Melanoma.

Posted: July 8th, 2010, 9:00am CDT

Condition: Malignant Melanoma
Interventions: Drug: bevacizumab [Avastin]; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010

Outcome Measures in Infant/Early Childhood Lung Disease w/ Chest CT Scanning & Lung Function Testing

Posted: July 6th, 2010, 9:00am CDT

Conditions: Soft Tissue Sarcoma; Lymphomas: Non-Hodgkin; Lymphomas: Non-Hodgkin Cutaneous Lymphoma; Lymphomas: Non-Hodgkin Diffuse Large B-Cell; Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell; Lymphomas: Non-Hodgkin Mantle Cell; Lymphomas: Non-Hodgkin Marginal Zone; Lymphomas: Non-Hodgkin Peripheral T-Cell; Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia; Neuroendocrine Tumors; Neuroendocrine Tumors Neuroblastoma; Lung Cancer; Lung Cancer Non-Small Cell Cancer (NSCLC); Lung Cancer Small Cell Lung Cancer (SCLC)
Interventions: Procedure: Intubation with a cuffed ET Tube; Procedure: CT scan Radiation
Sponsor: Stanford University
Recruiting - verified July 2010

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Posted: June 30th, 2010, 9:00am CDT

Conditions: Extensive Stage Small Cell Lung Cancer; Hereditary Paraganglioma; Male Breast Cancer; Malignant Paraganglioma; Metastatic Gastrointestinal Carcinoid Tumor; Metastatic Pheochromocytoma; Pancreatic Polypeptide Tumor; Recurrent Breast Cancer; Recurrent Cervical Cancer; Recurrent Endometrial Carcinoma; Recurrent Gastrointestinal Carcinoid Tumor; Recurrent Islet Cell Carcinoma; Recurrent Neuroendocrine Carcinoma of the Skin; Recurrent Non-small Cell Lung Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Pheochromocytoma; Recurrent Prostate Cancer; Recurrent Renal Cell Cancer; Recurrent Small Cell Lung Cancer; Recurrent Uterine Sarcoma; Regional Gastrointestinal Carcinoid Tumor; Regional Pheochromocytoma; Stage III Cervical Cancer; Stage III Endometrial Carcinoma; Stage III Neuroendocrine Carcinoma of the Skin; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage III Prostate Cancer; Stage III Renal Cell Cancer; Stage III Uterine Sarcoma; Stage IIIA Breast Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Breast Cancer; Stage IIIB Non-small Cell Lung Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Endometrial Carcinoma; Stage IV Neuroendocrine Carcinoma of the Skin; Stage IV Non-small Cell Lung Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor; Stage IV Prostate Cancer; Stage IV Renal Cell Cancer; Stage IV Uterine Sarcoma; Stage IVA Cervical Cancer; Stage IVB Cervical Cancer; Thyroid Gland Medullary Carcinoma
Interventions: Drug: temsirolimus; Drug: vinorelbine ditartrate
Sponsor: USC/Norris Comprehensive Cancer Center
Recruiting - verified June 2010

A Randomized Phase II Study of Interleukin-21 (rIL-21) Versus Dacarbazine (DTIC) in Patients With Metastatic or Recurrent Melanoma

Posted: June 28th, 2010, 9:00am CDT

Condition: Melanoma
Interventions: Drug: rIL-21; Drug: Dacarbazine
Sponsor: NCIC Clinical Trials Group
Recruiting - verified July 2010

Effect of Topical Imiquimod on Lentigo Maligna

Posted: June 24th, 2010, 9:00am CDT

Condition: Lentigo Maligna
Intervention: Drug: Imiquimod
Sponsors: University of Birmingham NHS Foundation Trust; Department of Health, United Kingdom
Recruiting - verified May 2010

Interpersonal Therapy for Depression in Breast Cancer

Posted: June 24th, 2010, 9:00am CDT

Condition: Major Depression
Interventions: Behavioral: Interpersonal Psychotherapy; Behavioral: Problem-Solving Therapy; Behavioral: Brief Supportive Psychotherapy
Sponsor: New York State Psychiatric Institute
Recruiting - verified June 2010

Evaluation of a New Vaccine Treatment for Patients With Metastatic Skin Cancer

Posted: June 22nd, 2010, 9:00am CDT

Conditions: Metastatic Melanoma; PRAME-positive
Intervention: Biological: Immunotherapeutic GSK2302025A, different formulations
Sponsor: GlaxoSmithKline
Recruiting - verified August 2010

Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

Posted: June 22nd, 2010, 9:00am CDT

Conditions: Cancer; Neuroendocrine; Ovarian Cancer; Colon Cancer
Interventions: Drug: JI-101; Drug: Everolimus
Sponsors: University of Utah; Jubilant Innovation Ltd.
Not yet recruiting - verified August 2010

A Study of RO5212054 (PLX3603) in Patients With BRAF V600-mutated Advanced Solid Tumours

Posted: June 11th, 2010, 9:00am CDT

Condition: Colorectal Cancer, Malignant Melanoma, Neoplasms
Intervention: Drug: RO5212054
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010

Temozolomide or MEK Inhibitor AZD6244 in Treating Patients With Metastatic Melanoma of the Eye

Posted: June 11th, 2010, 9:00am CDT

Condition: Intraocular Melanoma
Interventions: Drug: MEK inhibitor AZD6244; Drug: temozolomide
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified August 2010

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Posted: May 7th, 2010, 9:00am CDT

Conditions: Acoustic Schwannoma; Adult Anaplastic Meningioma; Adult Ependymoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Meningeal Hemangiopericytoma; Adult Papillary Meningioma; Neurofibromatosis Type 1; Neurofibromatosis Type 2; Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
Sponsor: Northwestern University
Not yet recruiting - verified May 2010

RO4929097 in Treating Patients With Stage IV Melanoma

Posted: May 7th, 2010, 9:00am CDT

Condition: Melanoma (Skin)
Interventions: Drug: gamma-secretase inhibitor RO4929097; Genetic: reverse transcriptase-polymerase chain reaction; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified May 2010

Ipilimumab + Temozolomide in Metastatic Melanoma

Posted: May 6th, 2010, 9:00am CDT

Condition: Metastatic Melanoma
Interventions: Drug: Ipilimumab; Drug: Temozolomide
Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified August 2010

NIR-Guided Sentinel Lymph Node Mapping in Melanoma

Posted: May 6th, 2010, 9:00am CDT

Condition: Melanoma
Intervention: Procedure: Sentinel Lymph Node Mapping
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center
Not yet recruiting - verified August 2010

Permalink for 'Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...'

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

Posted: May 5th, 2010, 9:00am CDT

Conditions: Skin Cancer; Melanoma; Metastatic Melanoma
Interventions: Biological: Aldesleukin; Biological: CD8 enriched Young TIL
Sponsor: National Cancer Institute (NCI)
Recruiting - verified April 2010

Permalink for 'Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery'

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Posted: April 27th, 2010, 9:00am CDT

Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: sargramostim
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Not yet recruiting - verified April 2010

A Study of LY2584702 With Erlotinib or Everolimus in Patients With Solid Tumors

Posted: April 22nd, 2010, 9:00am CDT

Conditions: Metastases, Neoplasm; Carcinoma, Non-Small Cell Lung; Renal Cell Carcinoma; Neuroendocrine Tumors
Interventions: Drug: LY2584702; Drug: Erlotinib; Drug: Everolimus
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

Posted: April 14th, 2010, 9:00am CDT

Conditions: Breast Cancer; Melanoma
Intervention: Drug: Lymphoseek
Sponsor: Neoprobe Corporation
Recruiting - verified August 2010

Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome

Posted: April 12th, 2010, 9:00am CDT

Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start); Drug: Mid-low dose LX1606 - Day 15 (start); Drug: Mid-high dose LX1606 - Day 29 (start); Drug: High dose LX1606 - Day 43 (start); Drug: Open Label Dose Extension
Sponsor: Lexicon Pharmaceuticals
Recruiting - verified June 2010

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Posted: April 12th, 2010, 9:00am CDT

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: RO5185426; Drug: RO5185426; Drug: RO5185426; Drug: RO5185426
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Posted: April 7th, 2010, 9:00am CDT

Conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size; Ciliary Body and Choroid Melanoma, Small Size; Iris Melanoma; Recurrent Intraocular Melanoma
Interventions: Biological: recombinant interferon alfa-2b; Drug: dacarbazine; Other: laboratory biomarker analysis
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified June 2010

Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy

Posted: March 10th, 2010, 9:00am CST

Condition: Neuroma, Acoustic
Interventions: Procedure: Microsurgery; Procedure: Stereotactic radiation therapy
Sponsors: Stanford University; University of Cincinnati; Baylor College of Medicine; Weill Medical College of Cornell University
Recruiting - verified May 2010

Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes

Posted: March 5th, 2010, 9:00am CST

Condition: Melanoma (Skin)
Interventions: Biological: HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine; Biological: HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine; Biological: autologous melanoma lysate-pulsed autologous dendritic cell vaccine; Biological: autologous melanoma lysate/tracer antigen KLH-pulsed autologous dendritic cell vaccine; Biological: dendritic cell-idiotype-keyhole limpet hemocyanin vaccine; Other: flow cytometry; Procedure: adjuvant therapy
Sponsor: Maria Sklodowska-Curie Memorial Cancer Center, Institute of Oncology
Recruiting - verified March 2010

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

Posted: March 4th, 2010, 9:00am CST

Condition: Malignant Melanoma
Interventions: Drug: Interleukin-2; Drug: Interleukin-2; Drug: Temozolomide
Sponsor: Penn State University
Recruiting - verified May 2010

$Permalink for 'Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors'$

Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors

Posted: February 25th, 2010, 9:00am CST

Conditions: Brain and Central Nervous System Tumors; Malignant Paraganglioma
Interventions: Drug: temozolomide; Drug: vorinostat; Genetic: DNA methylation analysis; Genetic: western blotting; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010

SciBase International Melanoma Pivotal Study

Posted: February 25th, 2010, 9:00am CST

Condition: Malignant Melanoma
Intervention: Device: SciBase III Electrical Impedance Spectrometer
Sponsor: SciBase AB
Recruiting - verified May 2010

A Phase I/II Study of TPI 287 - Temozolomide Combination in Melanoma

Posted: February 9th, 2010, 9:00am CST

Condition: Melanoma
Interventions: Drug: TPI 287; Drug: Temodar (Temozolomide)
Sponsors: M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Recruiting - verified August 2010

Phase II Study of Tesetaxel in Metastatic Melanoma

Posted: February 5th, 2010, 9:00am CST

Conditions: Advanced Melanoma; Cancer
Intervention: Drug: Tesetaxel
Sponsors: M.D. Anderson Cancer Center; Genta Incorporated
Recruiting - verified August 2010

Further Retrospect Clinical Study for FDA IND 78420 Exemption - Etoposide and Single Nucleotide Polymorphisms (SNPs)

Posted: February 2nd, 2010, 9:00am CST

Condition: Small Cell Lung Cancer
Intervention: Drug: ETOPOSIDE INJECTION
Sponsor: Medicine Invention Design, Inc
Not yet recruiting - verified August 2010

A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies

Posted: January 29th, 2010, 9:00am CST

Conditions: Bladder Cancer; Skin Cancers; Skin Cancer Cutaneous Lymphoma; Skin Cancer Basal Cell Carcinoma; Skin Cancer; Skin Cancer Melanoma; Skin Cancer Squamous Cell; Skin Cancer Other Skin Cancers
Intervention:
Sponsors: Stanford University; National Institutes of Health (NIH); Providence Foundation
Recruiting - verified June 2010

Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Posted: January 22nd, 2010, 9:00am CST

Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010

$Permalink for 'Seneca Valley Virus-001 in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features'$

Seneca Valley Virus-001 in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

Posted: January 13th, 2010, 9:00am CST

Conditions: Adrenocortical Carcinoma; Gastrointestinal Carcinoid Tumor; Kidney Cancer; Neuroblastoma; Retinoblastoma; Sarcoma
Interventions: Biological: Seneca Valley virus-001; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010

Permalink for 'MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies'

MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Posted: January 8th, 2010, 9:00am CST

Conditions: Advanced Nonhematological Malignancies; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastroesophageal Adenocarcinoma
Intervention: Drug: MLN8237
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010

Study of Weekly LOC-paclitaxel Injection for Melanoma

Posted: December 23rd, 2009, 9:00am CST

Condition: Melanoma
Intervention: Drug: LOC-paclitaxel
Sponsors: M.D. Anderson Cancer Center; Luitpold Pharmaceuticals
Recruiting - verified July 2010

Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors

Posted: December 16th, 2009, 9:00am CST

Conditions: Pancreatic Cancer; Liver Cancer; Lung Cancer; Lung Cancer Non-Small Cell Cancer (NSCLC); Lung Cancer Small Cell Lung Cancer (SCLC); Hepatobiliary Cancers; Hepatobiliary Cancers Liver; Hepatobiliary Cancers Hepatocellular Carcinoma (Hepatoma); Hepatobiliary Cancers Gallbladder; Hepatobiliary Cancers Bile Duct
Intervention: Procedure: MR Imaging
Sponsors: Stanford University; The American Association of Physicists in Medicine
Recruiting - verified June 2010

Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma

Posted: December 15th, 2009, 9:00am CST

Condition: Uveal Melanoma
Intervention: Drug: CP-675,206
Sponsor: Alberta Health Services
Recruiting - verified July 2010

A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma

Posted: December 15th, 2009, 9:00am CST

Condition: Malignant Melanoma
Interventions: Drug: bevacizumab [Avastin]; Drug: fotemustine
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified August 2010

$Permalink for 'PD 0332991 in Treating Patients With Refractory Solid Tumors'$

PD 0332991 in Treating Patients With Refractory Solid Tumors

Posted: December 10th, 2009, 9:00am CST

Conditions: Adult Solid Tumor; Adenocarcinoma of the Colon; Adenocarcinoma of the Rectum; Adult Central Nervous System Germ Cell Tumor; Adult Teratoma; Benign Teratoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Familial Testicular Germ Cell Tumor; HER2-negative Breast Cancer; HER2-positive Breast Cancer; Male Breast Cancer; Ovarian Immature Teratoma; Ovarian Mature Teratoma; Ovarian Monodermal and Highly Specialized Teratoma; Progesterone Receptor-negative Breast Cancer; Progesterone Receptor-positive Breast Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Extragonadal Germ Cell Tumor; Recurrent Extragonadal Non-seminomatous Germ Cell Tumor; Recurrent Extragonadal Seminoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Melanoma; Recurrent Ovarian Germ Cell Tumor; Recurrent Rectal Cancer; Stage III Extragonadal Non-seminomatous Germ Cell Tumor; Stage III Extragonadal Seminoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Ovarian Germ Cell Tumor; Stage IV Breast Cancer; Stage IV Colon Cancer; Stage IV Extragonadal Non-seminomatous Germ Cell Tumor; Stage IV Extragonadal Seminoma; Stage IV Melanoma; Stage IV Ovarian Germ Cell Tumor; Stage IV Rectal Cancer; Testicular Immature Teratoma; Testicular Mature Teratoma
Interventions: Drug: PD-0332991; Other: pharmacological study
Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2010

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Posted: December 8th, 2009, 9:00am CST

Condition: Extensive-Stage Small Cell Lung Cancer
Interventions: Drug: Amrubicin; Drug: Carboplatin; Drug: Pegfilgrastim
Sponsors: Sarah Cannon Research Institute; Celgene Corporation
Recruiting - verified June 2010

A Study of AMNN107 Against Dacarbazine (DTIC) in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Posted: December 7th, 2009, 9:00am CST

Condition: Melanoma
Interventions: Drug: nilotinib (AMN107); Drug: decarbazine (DTIC)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified August 2010

Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

Posted: December 3rd, 2009, 9:00am CST

Condition: Stage III Melanoma, Stage IV Melanoma
Intervention: Biological: MKC1106-MT
Sponsor: Mannkind Corporation
Not yet recruiting - verified August 2010

AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Posted: December 1st, 2009, 9:00am CST

Conditions: Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Intervention: Drug: AMG 479
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; H. Lee Moffitt Cancer Center and Research Institute; Amgen
Recruiting - verified August 2010

Permalink for 'Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma'

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Posted: December 1st, 2009, 9:00am CST

Condition: Malignant Melanoma
Interventions: Drug: BMS-936558 (MDX1106-04); Drug: Ipilimumab
Sponsors: Bristol-Myers Squibb; Medarex; Ono Pharma
Recruiting - verified August 2010

$Permalink for 'A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer'$

A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer

Posted: November 25th, 2009, 9:00am CST

Conditions: Melanoma; Carcinoma, Renal Cell
Intervention: Drug: Recombinant Human IL-15
Sponsor: National Cancer Institute (NCI)
Recruiting - verified July 2010

Permalink for 'Brief Title: Study to Determine Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Subjects Previously Treated With or Without a BRAF Inhibitor'

Brief Title: Study to Determine Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Subjects Previously Treated With or Without a BRAF Inhibitor

Posted: November 25th, 2009, 9:00am CST

Conditions: Cancer; Melanoma
Intervention: Drug: GSK1120212 Treatment
Sponsor: GlaxoSmithKline
Recruiting - verified June 2010

Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome

Posted: November 24th, 2009, 9:00am CST

Condition: Carcinoid Syndrome
Intervention: Drug: BIM 23A760
Sponsor: Ipsen
Recruiting - verified July 2010

Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma

Posted: November 20th, 2009, 9:00am CST

Condition: Melanoma (Skin)
Interventions: Other: follow-up care; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsor: University Medical Centre Groningen
Recruiting - verified July 2010

Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Posted: November 19th, 2009, 9:00am CST

Condition: Lung Cancer
Interventions: Biological: Seneca Valley virus-001; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010

Stage IV Surgery Versus Best Medical Therapy

Posted: November 12th, 2009, 9:00am CST

Condition: Stage IV Resectable Melanoma
Interventions: Procedure: Surgery; Procedure: Surgery plus 2 adjuvant doses of BCG; Other: best medical therapy
Sponsors: John Wayne Cancer Institute; Melanoma Research Alliance
Recruiting - verified May 2010

Partner Assistance in Learning and Performing Skin Self-Examination

Posted: November 11th, 2009, 9:00am CST

Condition: Melanoma
Interventions: Behavioral: Solo intervention and personal educational intervention; Behavioral: Solo intervention and brochure educational session; Behavioral: Paired interventional and brochure educational session; Behavioral: Paired intervention and personal educational intervention
Sponsors: Northwestern University; Loyola University; Dartmouth-Hitchcock Medical Center
Active, not recruiting - verified May 2010

Dose Escalation Study of MLN4924 in Adults With Melanoma

Posted: November 9th, 2009, 9:00am CST

Condition: Metastatic Melanoma
Intervention: Drug: MLN4924
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified June 2010

Permalink for 'Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor'

Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor

Posted: November 6th, 2009, 9:00am CST

Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified August 2010

A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

Posted: November 6th, 2009, 9:00am CST

Condition: Melanoma
Interventions: Drug: YM155; Drug: Docetaxel
Sponsor: Astellas Pharma Inc
Recruiting - verified August 2010

LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma

Posted: November 4th, 2009, 9:00am CST

Condition: Stage IV Melanoma
Intervention: Device: LC beads loaded with Doxorubicin
Sponsors: University of Louisville; Thomas Jefferson University; M.D. Anderson Cancer Center
Recruiting - verified June 2010

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

Posted: October 30th, 2009, 9:00am CDT

Conditions: Neuroendocrine Neoplasms; Thyroid Neoplasms; Parathyroid Neoplasms; Adrenal Neoplasm; Neuroblastoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2010

Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma

Posted: October 30th, 2009, 9:00am CDT

Condition: Melanoma (Skin)
Interventions: Biological: aldesleukin; Biological: therapeutic autologous lymphocytes; Drug: cyclophosphamide
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
No longer available - verified August 2010

Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma

Posted: October 30th, 2009, 9:00am CDT

Condition: Metastatic Melanoma
Interventions: Drug: sunitinib malate; Drug: temozolomide
Sponsors: University of California, Los Angeles; National Cancer Institute (NCI)
Recruiting - verified June 2010

A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma

Posted: October 30th, 2009, 9:00am CDT

Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified August 2010

A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma

Posted: October 30th, 2009, 9:00am CDT

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010

Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection

Posted: October 29th, 2009, 9:00am CDT

Condition: Melanoma
Intervention: Behavioral: screening questionnaire
Sponsors: Memorial Sloan-Kettering Cancer Center; University of British Columbia; San Diego State University; Stony Brook University
Recruiting - verified June 2010

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

Posted: October 27th, 2009, 9:00am CDT

Condition: Metastatic Melanoma
Interventions: Procedure: Surgery; Drug: Lymphodepletion
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified May 2010

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

Posted: October 21st, 2009, 9:00am CDT

Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: Drug cocktail
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified August 2010

Effect of Bosentan in Patients With Metastatic Melanoma Treated With Dacarbazine (DTIC)

Posted: October 14th, 2009, 9:00am CDT

Condition: Melanoma
Interventions: Drug: Bosentan; Drug: Placebo
Sponsor: Actelion
Completed - verified July 2010

Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma

Posted: October 7th, 2009, 9:00am CDT

Condition: Melanoma (Skin)
Interventions: Genetic: gene expression analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: medical chart review
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2010

Study of Panobinostat in Patients With Neuroendocrine Tumors

Posted: September 25th, 2009, 9:00am CDT

Condition: Neuroendocrine Tumors
Intervention: Drug: panobinostat (LBH589)
Sponsors: University of Wisconsin, Madison; Novartis Pharmaceuticals
Recruiting - verified May 2010

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

Posted: September 24th, 2009, 9:00am CDT

Condition: Neoplasms
Interventions: Drug: RG1507; Drug: RAD001
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified August 2010

$Permalink for 'Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer'$

Bendamustine as Second-Line Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Posted: September 24th, 2009, 9:00am CDT

Condition: Lung Cancer
Intervention: Drug: bendamustine hydrochloride
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2010

Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Posted: September 24th, 2009, 9:00am CDT

Condition: Metastatic Melanoma
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Oncolytics Biotech; University of Texas
Recruiting - verified July 2010

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

Posted: September 16th, 2009, 9:00am CDT

Conditions: Anxiety; Stage IV Melanoma
Interventions: Drug: psilocybin; Drug: psilocybin
Sponsor: Multidisciplinary Association for Psychedelic Studies
Not yet recruiting - verified July 2010

Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma

Posted: September 11th, 2009, 9:00am CDT

Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: everolimus; Drug: paclitaxel
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Suspended - verified August 2010

Rare Cancer News & Clinical Trials » Endocrine/Neuroendocrine

Feeds

Endocrine/Neuroendocrine (235 unread)

Fetched: September 1st, 2010, 9:31am CDT

Fetched: September 1st, 2010, 9:31am CDT

Fetched: September 1st, 2010, 9:31am CDT

Fetched: September 1st, 2010, 9:31am CDT

Fetched: September 1st, 2010, 9:31am CDT

Fetched: September 1st, 2010, 9:31am CDT

Fetched: August 17th, 2010, 9:13am CDT

Fetched: August 17th, 2010, 9:13am CDT

Fetched: August 17th, 2010, 9:13am CDT

Fetched: August 17th, 2010, 9:13am CDT

Fetched: August 17th, 2010, 9:13am CDT

Fetched: August 17th, 2010, 9:13am CDT

Fetched: August 8th, 2010, 7:33pm CDT

Fetched: August 8th, 2010, 7:33pm CDT

Fetched: August 8th, 2010, 7:33pm CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: August 4th, 2010, 9:26am CDT

Fetched: July 11th, 2010, 1:35pm CDT

Fetched: July 11th, 2010, 1:35pm CDT

Fetched: July 11th, 2010, 1:35pm CDT

Fetched: July 11th, 2010, 1:35pm CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Fetched: June 26th, 2010, 9:50am CDT

Posted: September 1st, 2010, 10:00pm CDT

Posted: September 1st, 2010, 10:00pm CDT

Posted: September 1st, 2010, 10:00pm CDT

Posted: August 17th, 2010, 10:00pm CDT

Posted: August 17th, 2010, 10:00pm CDT

Posted: August 17th, 2010, 10:00pm CDT

Posted: August 17th, 2010, 10:00pm CDT

Posted: August 17th, 2010, 10:00pm CDT

Posted: August 13th, 2010, 10:00pm CDT

Posted: August 13th, 2010, 10:00pm CDT

Posted: August 13th, 2010, 10:00pm CDT

Posted: August 13th, 2010, 10:00pm CDT

Posted: August 10th, 2010, 10:00pm CDT

Posted: August 10th, 2010, 10:00pm CDT

Posted: August 6th, 2010, 10:00pm CDT

Posted: August 4th, 2010, 10:00pm CDT

Posted: August 4th, 2010, 10:00pm CDT

Posted: August 4th, 2010, 10:00pm CDT

Posted: August 4th, 2010, 10:00pm CDT

Posted: August 4th, 2010, 10:00pm CDT

Posted: August 4th, 2010, 10:00pm CDT